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ABSTRACT 
 The field of salvinorin chemistry represents a novel and emerging field of opioid 
research.  The novelty is derived from the lead pharmacophore:  salvinorin A — a neoclerodane 
diterpenoid natural product isolated from Salvia divinorum.  Salvinorin A represents a 
pharmacologically unique compound in that it is the first known  non-nitrogenous KOR subtype-
selective agonist, exhibits a comparatively safe physiological profile with no reports of 
toxicological effects in clinical trials, and, most importantly, has a steadily growing body of 
literature indicating potentially useful clinical applications (e.g. antinociceptive, anti-addictive, 
antipruritic, neuroprotective, etc.).  This has encouraged the development of analogues as 
essential molecular probes to elucidate the structure-activity-relationship of the salvinorin-class. 
 In this study, we expand the current field of salvinorin chemistry through the design, 
development, and preclinical evaluation of a series of C(22)-fused heteroaromatic salvinorin A 
analogues.  Our in vitro models include:  opioid receptor competitive radioligand binding affinity 
and functional [
35S]GTP[γS] binding activity assays; while our in vivo models include: 
antinociceptive, antidepressant, and anxiolytic related assays.  This resulted in three analogues 
exhibiting EC50 sub-200 nM functional activity, of which two displayed antinociceptive 
activities, with one also demonstrating antidepressant-like activity.  As such, this study further 
supports the importance of the continued development of new salvinorin A analogues as 
essential research tools to ascertain potential three-dimensional ligand binding requirements, 
functional activities, and pharmacological consequences mediated through the clinically 
important opioid receptors. 
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CHAPTER 1:  Salvia divinorum 
In 1939 anthropologist Jean Bassett Johnson reported the use of hallucinogenic 
mushrooms by the Mazatec in Mexico, as well as, the use of an infusion of leaves from a plant 
called hierba María for similar purposes (Johnson, 1939).  However, he was unable to secure a 
suitable herbarium specimen to allow for botanical taxonomy to be established.  It was not until 
1962 that Robert Gordon Wasson, while exploring the Sierra Mazateca in Oaxaca Mexico and 
studying the Mazatec use of hallucinogenic mushrooms, was able to both secure a suitable 
herbarium specimen, as well as, substantiate the previously reported activity of prepared 
infusions of the plant material by participating in its ceremonial use: 
 
The effect of the leaves came sooner than would have been  
the case with the mushrooms, was less sweeping, and lasted  
a shorter time. There was not the slightest doubt about the effect,  
but it did not go beyond the initial effect of the mushrooms –  
dancing colors in elaborate, three-dimensional designs. Whether  
a larger dose would have produced a greater effect, I do not know.   
(Wasson, 1962) 
 
 
Ritual preparation consists of pairing “flawless” leaves together, 50-100, and masticating 
the leaves for effect.  Alternatively, and the method used by Wasson, is to grind the leaves with 
water, straining and consuming the resulting infusion for effect (Wasson, 1962).  The 
ceremonious use of this plant, described by both Wasson and earlier investigators such as 
Blas Pablo Reko, indicate that the purpose is divinatory in nature (Reko, 1945 and Wasson, 
 2 
 
Figure 1.  Salvia divinorum line drawing.  
Adapted from Schultes and Hofmann, 1973. 
1962).  A curandero would initiate the ritual to divine the cause of disease in participating 
patients.  It is the divinatory use of this plant and, especially, the use of infusions prepared 
from its leaves that led Wasson to propose that Salvia divinorum may represent the ancient 
Aztec plant pipiltzintzintli (Wasson, 1963).  Beyond the use of this plant for divinatory purposes 
it is also used medicinally by the Mazatecs to treat diarrhea, headaches, rheumatism and a 
Mazatec illness known as panzón de barrego [sic] (swollen belly).  Additionally, it is used in 
patients that are near death to revive and alleviate them of their illness (Johnson, 1939 and 
Valdés III et al., 1983).   
The herbarium specimen obtained 
by Wasson was provided to Carl Epling 
and Carlos D. Játiva-M. who identified it as 
an undescribed species in the Lamiaceae 
family designating the new species as 
Salvia divinorum (Epling and Játiva-M., 
1962) (Figure 1, line drawing; Figures 2 
and 3, photographs of cultivated specimen; 
Figure 4, photograph of specimen in natural 
habitat).  Botanically this species is 
characterized as a perennial herb averaging 
approximately a meter in height.  Mature 
leaves are approximate 14 cm long (Figure 
5A), ovate, acuminate, basally rounded, 
crenate-serrate with hairs in sinuses along the margins, glabrate but hirtellous along the lower 
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veins that attenuate into a petiole 2-3 cm long.  The inflorescence is characterized by being 
bluish, slightly pubescent, in full panicles on branches approximately 35 cm long, with a violet 
calyx tube, approximately 15 mm long with superior lip 1.5 mm long and three impressed veins,  
lip 6 mm tall, inferior lip shorter and incurved.   
 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Photograph of cultivated Salvia divinorum plant illustrating general 
growth habit. 
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Figure 3.  Photograph of cultivated Salvia divinorum plant illustrating 
characteristic square stem and oppositely decussate leafing pattern. 
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Figure 4.  Photograph of Salvia divinorum plant in natural habitat that illustrates the toppling 
growth pattern observed in this species.   
 
[Creative Commons image:  CC BY-SA 3.0, 
https://commons.wikimedia.org/w/index.php?curid =157218] 
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A.                  B.     
 
 
Figure 5.  [A]  Photograph of Salvia divinorum leaf, fresh.  [B] Photograph of 
lyophilized Salvia divinorum leaf material coarsely ground prior to extraction. 
The corolla tube is white, sigmoid, 22 mm long, with superior lip 6 mm tall, inferior lip 
shorter and incurved.  The stamens are inserted near the mouth of the tube:  style hirtellous, with 
posterior branch long, obtuse, flat, anterior carinate branch (Epling and Játiva-M., 1962; Schultes 
and Hofmann, 1973; Valdés III et al., 1987).  Additionally, it was widely thought that this plant 
may represent a cultivar as it was essentially unknown outside of curandero cultivated patches 
isolated in the Sierra Mazateca highlands (Ott, 1993).  However, this appears to be due to a 
characteristically low seed-set and limited seed viability observed in this irregularly flowering 
plant as seed-set was first demonstrated in 1987 (Valdés III et al., 1987).  Laboratory cultivation 
experiments revealed low pollen viability (approximately 56% failure) from pollinated stigmas 
resulting in low seed-set (Jenks et al., 2011 and Reisfield, 1993).  
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Figure 6.  Distribution of Salvia divinorum within the Mazatec territory.  See 
gray zone within inset region of Oaxaca.  Adapted from Casselman et al., 2014. 
Salvia divinorum, while reported at several locations ranging from 500 to 1500 meters in 
altitude, has a limited geographical distribution within the highlands of the Sierra Mazateca in 
Oaxaca, Mexico (Figure 6) (Casselman et al., 2014 and Reisfield, 1993).  This range is typified 
by tropical montane cloud-forests (i.e. persistent cloud cover resulting in high humidity).  As an 
herbaceous plant Salvia divinorum represents an understory member whose populations are 
generally in partial to full shade conditions in nutrient-rich, moist soils often found near water 
courses.  Either naturally, by toppling over (Figure 4), or aided by curanderos Salvia divinorum 
is propagated primarily vegetatively through clonal growth.  
The first live collection of Salvia divinorum that was successfully propagated outside of 
Oaxaca was deposited by Sterling Bunnell at the University of California, Los Angeles Botanical 
Garden in 1963 and consisted of a single specimen (Siebert, 2003).  Due to the notable low seed-
set rate, usual method of clonal propagation, and limited number of reported live collections it is 
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suggested that this plant is likely the progenitor of the vast majority of propagated Salvia 
divinorum currently available outside of Oaxaca, Mexico.  Intraspecific genetic studies of five 
populations obtained from within Sierra Mazateca revealed a limited genetic diversity, as well 
as, placed the species outside of the Salvia “core" subgenus Calosphace with Salvia venulosa 
being supported as its closest related species by both ITS and cpDNA phylogenetic assessment 
(Jenks et al., 2011).  Additionally, the authors indicated that the species appear reproductively 
capable but that anthropogenically-mediated clonal propagation may negatively affect this 
capacity.  However, they concluded that further studies are needed into the sexual reproductive 
capacity and genetic diversity of the species. 
Phytochemical investigation into the active constituents of Salvia divinorum began with 
Albert Hofmann in 1964, due in part to his close association with Wasson, having accompanied 
the 1962 expedition (Wasson, 1962).  However, more important was Hofmann’s unparalleled 
expertise with hallucinogenic compounds (Figure 7):  having discovered lysergic acid 
diethylamide (LSD; initial synthesis in 1938 and re-examination in 1943), and more relevantly, 
his experience working with other Mazatecan hallucinogenic species from Mexico, including the 
identification of psilocybin and psilocin as active constituents from the hallucinogenic 
mushroom Psilocybe mexicana (subsequently, isolated from numerous Psilocybe species; 
Nahuatl:  teonanácatl) and the identification of lysergic acid amide as the active constituent from 
Turbina corymbosa seeds (Nahuatl:  ololiuhqui) (Hofmann, 1964). 
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Lysergic acid diethylamide   Lysergic acid amide    
    
 
 
Psilocybin     Psilocin 
 
                   
 
 
 
Figure 7.  Hallucinogenic alkaloids discovered by Hofmann. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This pattern of alkaloids consistently being the perceptiotropic constituent suggested that 
a similar pattern may be observed with Salvia divinorum.  Starting with an infusion prepared in 
Mexico and preserved with alcohol Hofmann attempted, and failed, to isolate the causative 
alkaloid upon return to his laboratory in Basel, Switzerland.   When he reassessed the alcohol 
preserved infusion via experimenter self-administration he discovered that the material was 
inactive — concluding that the perceptiotropic principle was unstable in solution and that “the 
problem of the magic plant ska María Pastora still awaits solution” (Hofmann, 1979).  
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Figure 8.  Structure of salvinorin A. 
 
 
CHAPTER 2:  Salvinorin A 
Hofmann’s Solution 
The solution to Hofmann’s Salvia divinorum problem continued to remain elusive until 
1984 when Leander J. Valdes, III and collaborators utilized an in vivo bioassay-guided approach 
toward fractioning lyophilized leaf material (Figure 5B) (Valdes, III, et al. 1984).  Employing a 
modified open field test (OFT), column fractions of the extracted leaf material were assessed at 
each stage of silica gel chromatographic purification for altered activity in mice.  This process 
led to the isolation of a neo-clerodane diterpenoid which they designated as divinorin A.  During 
the publication process they learned that the compound, divinorin A, had been previously 
reported by Alfredo Ortega in 1982 
as salvinorin A (Ortega et al., 
1982).  The Ortega group had 
utilized a blind-fractionation 
process to isolate salvinorin A 
(Figure 8) and had not evaluated 
the compound pharmacologically. 
However, it wasn’t until 
1994 that the first pharmacological 
evaluation of salvinorin A in 
humans was reported (Siebert, 
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1994).  In this study, Daniel J. Siebert, with six volunteers, assessed both traditional Salvia 
divinorum leaf infusions (gastrointestinal absorption versus buccal absorption) and pure 
salvinorin A (buccal absorption versus vaporized inhalation absorption).  This study was 
important as it was the first to verify the perceptiotropic effects of salvinorin A in humans.  
Additionally, it served to establish the initial pharmacology of the compound in humans.  Siebert 
discovered that salvinorin A is an extremely potent perceptiotropic substance, which is active at 
200-500 μg when vaporized and inhaled (they tested doses up to 2.6 mg with no adverse effects 
observed). 
Pharmacologically they established that vaporization/inhalation effects are markedly 
different from the more traditional route of administration.  The traditional route (i.e. buccal 
absorption) results in perceptiotropic effects that are as described in the earlier literature:  mild 
hallucinogenic activity that takes approximately ten minutes before initial effects are felt, that 
plateau for about one hour before gradually subsiding over the next hour.  This contrasts sharply 
when administered via vaporization and inhalation:  the full effects are best described as 
dissociatively hallucinogenic and is experienced in approximately thirty seconds and last for 
five-to-ten minutes.  In an attempt to establish the pharmacological target of salvinorin A Siebert 
collaborated with David Nichols to screen at a series of likely neuroreceptors, such as the 
dopamine and serotonergic receptors.  However, they found no significant activity at any of the 
screened receptors (Siebert, 1994).   
It wasn’t until 2002 when Siebert collaborated with Bryan L. Roth of the National 
Institute of Mental Health Psychoactive Drug Screening Program (NIMH-PDSP) that a 
pharmacological target was elucidated.  Employing a competitive radioligand binding assay 
against fifty cloned human G-protein-coupled receptors (GPCRs) they discovered, surprisingly, 
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Figure 9.  Screening of Salvinorin A in competitive radioligand binding assays 
against fifty cloned human GPCRs at 10μM, demonstrating selectivity at hKOR.  
LSD is shown as comparison.  Roth et al. 2002.  Reprinted with permission. 
that salvinorin A not only bound to the opioid receptors, but was subtype selective, exhibiting 
potent selectivity for the kappa opioid receptor (KOR) subtype (Figure 9).  This was followed 
with functional assessment utilizing a [
35
S] GTP[γS] assay at KOR that revealed salvinorin A 
was a potent agonist with an EC50 of approximately 1 nM.  This represents the first report of a 
non-nitrogenous subtype-selective opioid receptor agonist (Roth et al.¸ 2002).  It also represents 
the solution to “the problem of the magic plant ska María Pastora” posed by Hofmann that was 
forty years in the making and the beginnings of the field of salvinorin chemistry. 
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The Opioid System — A Clinically Important Target 
 
The opioid system is crucially involved in the modulation of antinociception and 
associated behaviors.  Chronic pain affects an estimated 100 million Americans, has associated 
costs exceeding $600 billion per year in lost productivity and medical expenses, and the 
currently available drug therapies consist primarily of classical opioid analgesics such as 
morphine and closely related analogues (Prisinzano, 2013).  Compounding the issue, admissions 
for treatment of prescription opioid abuse has increased by an astounding 400% over the past 15 
years and the death rate (estimated by the CDC at 90 Americans per day in 2015) from opioid 
drug use exceeds all other drug classes (Ling et al, 2011; Nielsen and Bruno, 2011; Rudd et al., 
2016).  Beyond legal production it is estimated that annual production of illicit opioids exceeds 
$800 billion (Rinner and Hudlicky, 2012).  In spite of these problems, opioids continue to be the 
most prescribed, and abused, class of drugs (Negri et al., 2013). 
Extending beyond antinociception, numerous studies have indicated involvement of this 
system in a diverse array of critical behavioral states, including:  addiction, anxiety, and 
depression — further reinforcing the clinical importance of this system (Al-Hasani and Bruchas, 
2011; Lalanne et al., 2014; Ling et al., 2011).  The opioid system is composed of four G-protein-
coupled receptors (GPCRs) that belong to the Rhodopsin-like, Class A, subfamily that include 
opioid receptors (OR):  delta (DOR), kappa (KOR), mu (MOR), and nociception (NOR) — with 
an increasing number pharmacologically defined subtypes for each resulting from alternative 
splicing, post-translational modification, and/or receptor oligomerization (Al-Hasani and 
Bruchas, 2011; Stein, 2016; Urbano et al., 2014; Ying-Xian et al., 2003). 
The opioid receptors are widely expressed throughout both the peripheral and central 
nervous systems, as well as throughout diverse systems such as:  cardiovascular, gastrointestinal, 
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Table 1. Representative Endogenous Opioid Peptides. 
Primary 
Target 
Sequence 
(Three-Letter-Code) 
Peptide 
DOR Tyr-Gly-Gly-Phe-Met [Met
5
]-encephalin 
DOR Tyr-Gly-Gly-Phe-Leu [Leu
5
]-encephalin 
KOR 
 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys dynorphin A 
KOR Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr dynorphin B 
KOR 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-
Arg-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Tyr-Glu-Glu-Leu-
Phe-Asp-Val 
leumorphin 
MOR 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-
Val-Thr 
α-endorphin 
MOR 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-
Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-
Lys-Gly-Glu 
β-endorphin 
MOR 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-
Val-Thr-Leu 
γ-endorphin 
MOR Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys α-neo-endorphin 
MOR Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro β-neo-endorphin 
NOR 
Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-
Leu-Ala-Asn-Gln 
Nociceptin 
Compiled from the following references:  Hazum et al., 1979; Janecka et al., 2004; Kangawa 
et al., 1981; Minamino et al., 1981; Nakao et al., 1983; Suda  et al., 1984; Toll et al., 2016. 
 
and reproductive (Feng et al., 2012).  Physiologically, DOR, KOR, and MOR are each 
modulated by several endogenous neuropeptides that are subtype cognate (Table 1).  For  
example, DOR is activated by enkephalins (Figure 10), KOR by dynorphins (Figure 11)  and 
MOR by endorphins (Figure 12) — however, this is a preferential affinity as there is some 
degree of non-selectivity exhibited by these representative endogenous ligands across the  
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[Leu
5
]-enkephalin 
 
 
 
[Met
5
]-enkephalin 
 
Figure 10.   Structures of representative encephalin-class endogenous opioid peptides. 
subtypes (Albert-Vartanian et al., 2014; Phan et al., 2012).    The nociceptin opioid receptor 
(NOR) represents an atypical opioid receptor in that it possesses limited pharmacological 
response to classical opioids, despite assignment based on amino acid sequence homology, its 
cognate endogenous peptide has been identified as a unique heptadecapeptide ligand designated 
as nociceptin (Meunier et al., 1995).   
Complications in clinically targeting opioid receptor subtypes, and their variants, arises 
from the high degree of amino acid residue homology observed between DOR, KOR, MOR, and 
NOR — with greater than 70% homology observed in the II, III, VII transmembrane (TM) 
helices (TM2, TM3, TM7), 50% homology between I, V, VI (TM1, TM5, TM6), and 24% 
homology within IV (TM4) (Toll et al., 2016).  Despite this high degree of homology, the 
receptor subtypes exhibit a range of pharmacological distinctiveness including desirable 
properties such as analgesia and anxiolytic effects or undesirable properties such as anhedonia or 
impaired coordination.  
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Dynorphin A 
 
 
Dynorphin B 
 
 
Figure 11.   Structures of representative dynorphin-class endogenous opioid 
peptides. 
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Figure 12.   Structure of representative endorphin-class endogenous opioid peptide. 
α-endorphin 
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Morphine Chemistry — Origins of Classical Opioids 
It is the pursuit of these desirable drug-induced properties that has fostered research into 
small molecule ligands targeting the opioid receptors and to a degree that far outdistances that of 
current peptide research.  This is, in large part, due to the rather lengthy history of 
ethnomedicinal use of the plant Papaver somniferum — otherwise known as opium poppy.  
Some of the earliest archaeological evidence indicating human cultivation of Papaver 
somniferum dates back to approximately 5700 BCE from the site of an early European Neolithic 
settlement discovered submerged under Lake Bracciano, Italy (Merlin 2003).  Evidence of the 
use of this plant continues during the Bronze Age (circa 1550-1100 BCE) with the discovery of 
numerous poppy capsule artifacts (Figure 13) present throughout mainland Greece indicating a 
 
Figure 13.  Greek poppy capsule artifact.  Merlin, 2003.  Reprinted 
with permission. 
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Figure 14.  Lanced Papaver somniferum 
seed pod exuding opium latex.  [Public 
Domain image from TeunSpaans, 2017] 
 
likely significance beyond mere food substance and a connection with ritual and/or medicinal 
use of the plant.  This was later substantiated in the writings of Hippocrates of Kos during the 
Classical Greece period (circa 500-400 BCE) (Kritikos and Papadaki, 1967).  However, the first 
written record of the medicinal use of Papaver somniferum was much earlier, being found in the 
Ebers Papyrus from Egypt, written circa 1550 BCE, that indicated the use of this plant for 
sedative effects (Atanasov et al., 2015). 
 Eventually this usage extended into analgesic effects by the Archaic Greece period 
(circa 800-500 BCE) preceding the Classical Greece period and possibly noted in The Odyssey: 
 
…she cast a drug into the wine of which they drank to lull 
all pain and anger and bring forgetfulness of every sorrow.  
(Homer, early 8
th
 Century BCE) 
 
The harvesting of the milky-white latex (Figure 
14) (Greek opos ; opium) that is collected by 
lancing unripe seed capsules of Papaver 
somniferum which upon drying results in a 
viscous, dark brown-black resinous material 
that is raw opium (Figure 15) (the Greek 
μηκώνιον; mekonion).  However, it is likely 
that analgesic use extends even further in 
antiquity, as archeological evidence indicates 
that as early as 3000 BCE the Sumerians 
referred to the opium poppy as “hul gil” — the 
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Figure 15.  Dried opium.  [Public Domain image 
from the DEA, 2017] 
plant of joy (Brownstein, 1993).   
 Additionally, during this time (circa 1300-1000 BCE) trade had seen the spread of 
Papaver somniferum, as both a food and medicinal substance, from the Asia Minor and 
Mediterranean regions throughout India, China, and Europe — essentially through all parts of 
the then known world.  During this lengthy period, numerous routes of opium administration had 
been created; the two most widely used were dissolving the opium in solution such as wine (see 
The Odyssey reference above by Homer) or other alcohol (e.g. laudanum) or vaporization of the 
opium and inhalation of the opium vapors. 
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Figure 16.  Structure of morphine. 
It wasn’t until the early 1800’s (CE) that advancements in the medicinal use of opium 
occurred.  In 1806 Friedrich Wilhelm Sertürner established the initial pharmacochemical 
properties of a crystalline substance isolated from opium that he named Morphium, after the 
Greek god of Dreams (this compound was later referred to as Morphine).  The sleep inducing 
and analgesic activity was established first in canine test animals and subsequently verified by 
experimenter self-administration (Atanasov et al., 2015; Brownstein, 1993).  This compound 
represents the first isolated alkaloid and established the field of alkaloid-chemistry and, more 
specifically, the field of morphine-chemistry.  The structure of morphine remained elusive until 
1952 when sufficient technological advancements finally allowed for the verification via total 
synthesis by Marshall D. Gates (Gates, 1952) of the structure (Figure 16) proposed in 1925 by 
Sir Robert Robinson (Gulland and Robinson, 1925) [For an excellent review summarizing the 
historical developments of the total-synthesis of morphine since 1952 see:  Rinner and Hudlicky, 
2012.].  This was the culmination of a 146-year endeavor that resulted in a two column 
publication that concluded:  “With this, the first synthesis of morphine is complete.” 
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Figure 17.  Bayer Heroin bottle.  [Public 
Domain image from Mpv_51, 2017] 
 However, the utility of morphine in relieving pain was not without undesirable side-
effects, perhaps most notable has been that of addiction.  The addictive use of opium has been 
reported since antiquity in some of the earliest documents relating to the opium trade throughout 
Asia, India, and Asia Minor (Brownstein, 1993).  Even prior to the first total synthesis of 
morphine in 1952, efforts had been directed at semi-synthetic structural modification to limit or 
avoid addiction potential.  The first reported 
success was in 1874 with the synthesis of an 
acetylated form of morphine (Wright, 1874).  
However, it wasn’t until 1893 that Felix 
Hofmann re-synthesized this same analogue 
for the Bayer Company, who decided upon 
a heroic name for the compound:  Heroin 
(from the German heroisch).  Bayer 
marketed Heroin (Figure 17) as lacking the 
narcotism (i.e. addictive properties) seen 
with morphine use — unfortunately this 
ultimately was found to be inaccurate 
(Hofmann, 2017).  
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Salvinorin A — A Novel Opioid 
Pharmacological advancements within the field of morphine chemistry has yielded 
thousands of analogues; however the ability to clearly separate desirable drug-like properties 
such as antinociceptive activity from undesirable side-effects continues to remain elusive 
(Kieffer, 2016).  In this pursuit, overwhelmingly, MOR has been the primary opioid receptor 
targeted for scientific study due to the effective antinociceptive activity of classical opioid 
agonists that primarily mediate through this receptor subtype.  However, there are numerous 
adverse side-effects, beyond undesirable respiratory effects, MOR activation is complexed with 
the dopaminergic reward pathway promoting euphoria, ultimately resulting in both physiological 
and psychological dependence (Albert-Vartanian et al., 2016; Shook et al. 1990).  Nevertheless, 
MOR agonists continue to be the primary pharmacologic antinociceptive class of drugs clinically 
used to treat pain.  This has led to MOR agonists based on morphine-chemistry becoming the 
most misused class of pharmaceutical agents in the world, which has stimulated interest in 
targeting alternative opioid subtypes that are devoid of these physiologically adverse effects 
(Negri et al., 2013).   
The kappa opioid receptor (KOR) subtype, which is the target of salvinorin A, is widely 
expressed throughout both central nervous tissues (brain and spinal cord), as well as, the 
peripheral tissues, such as the gastrointestinal tract.  Within the brain KOR is highly expressed in 
the amygdala, hippocampus, hypothalamus, and striatum — regions associated with behavioral 
functions including cognitive processing, emotional function, pain and stress response (Urbano 
et al., 2014; Maillet et al.,2015).  Furthermore, activation of KOR is generally not associated 
with the physiologically adverse effects observed in MOR activation (i.e. physical dependence or 
respiratory failure).  This has generated interest in KOR becoming a potential clinical target for 
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Figure 18.  Structure of U-69,593. 
pain management, as well as, for the treatment of psychiatric conditions including anxiety and 
depression.  However, historically, KOR has been pharmacologically avoided due to associated 
undesirable side-effects including anhedonia, dysphoria, and perceptiotropic effects (e.g. 
hallucinations) (Lalanne et al., 2014; Maillet et al., 2015). Advancing within this paradigm there 
has been significant work to elucidate the mechanism of salvinorin A activity with relation to 
KOR due to the novel aspect of it being the first known non-nitrogenous opioid receptor agonist 
(Roth et al., 2002). 
Early computational studies were restricted to X-ray crystallographic data limited in 
scope to “in-active” crystal structures derived from antagonist bound receptors (Roth et al., 
2002).  The most common crystal structure utilized for this computational work has been human 
KOR complexed with JDTic (PDB ID:  4DJH) (Polepally et al., 2014; Wu et al., 2012).  To 
address this limitation, site-directed mutagenic studies were undertaken to establish potential key 
residues to aid in defining the salvinorin A binding pocket (Kane et al., 2006; Van et al., 2013; 
Yan et al., 2005).  Separately, these studies corroborated the importance of residues Y320 and 
Tyr-139 of TM3 and residues Tyr-119, Tyr-312, Tyr-313, and Tyr-320 of TM7 as essential for 
the binding of salvinorin A in KOR — it has been proposed that this aromatic cluster may form a 
key binding pocket (Kane et al., 2008; Kane et al., 2006; Yan et al., 2005).  Additionally, non-
aromatic residues Gln-115 of TM2 and Ile-316 of 
TM3 were also shown to be significant in 
salvinorin A binding.  In particular, loss of Ile-316 
resulted in abolishment of salvinorin A binding at 
KOR (Kane et al., 2008; Van et al., 2013; Yan et 
al., 2005).  These residues were contrast with the 
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Figure 19.  Putative binding orientation of salvinorin A structure within KOR 
(Kane et al., 2006). 
prototypical U-69,593 (Figure 18) KOR subtype selective agonist and the endogenous peptide 
dynorphin A, both of which displayed different requirements at these residues (Kane et al., 2006; 
Yan et al., 2005). 
Together these studies were used to establish putative key binding regions of salvinorin A 
within KOR which suggested that the tricyclic core may vertically span (Figure 19) the receptor 
between TM2 and TM7 (Kane et al., 2006; Yan et al., 2005).  Perhaps most interestingly, these 
residues differ significantly from the classical opioid ligand binding pocket centrally located in 
the receptor, spanning TM3 and TM6, characterized by conserved Asp-138 and Asp147 residue 
interactions — potentially indicating an unique binding mode for salvinorin A within the opioid 
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receptor (Kane et al., 2008; Manglik et al., 2012; Surratt et al., 1994; Yan et al., 2005; Yuan et 
al., 2015). 
Expanding beyond a structural understanding of salvinorin A significant work has been 
undertaken to build upon the initial pharmacological results reported by Bryan L. Roth in 2002 
that established salvinorin A as the first known non-nitrogenous opioid receptor agonist that was 
subtype selective for KOR (Roth et al., 2002).   Their study used a competitive radioligand 
binding affinity assay that employed [
3
H]-bremazocine and assessed salvinorin A at KOR 
reporting a Ki of 4 nM.  This was then followed by a functional assay that utilized 
[
35S]Guanosine 5’-(γ-thio)-triphosphate ([35S]GTP[γS]) as a measurable radioligand to assess the 
activation of the receptor through binding of guanosine triphosphate (GTP) for which they 
reported an EC50 of 1 nM for salvinorin A.  This activity was subsequently corroborated in a 
2004 study that reported similar values for salvinorin A at KOR with a binding affinity Ki of 18 
nM and functional assessment of [
35S]GTP[γS] binding activity reported at an EC50 of 0.63 nM 
(Chavkin et al., 2004).  
Toxicological assessment of salvinorin A (0.4 - 6.4 mg/kg, IP — a dose range 
significantly greater than used by humans) for acute physiological and chronic histological 
effects in mice established that there were no significant alterations in at any endpoint 
(physiological measures:  pulse pressure, galvanic skin response, cardiac conduction, body 
temperature; histological measures:  spleen, liver, kidney, brain, bone marrow, and blood).  
Researchers concluded that the data suggested that potential toxicity from salvinorin A may be 
quite low (Mowry et al., 2003).  Furthermore, this lack of acute toxicity has been substantiated in 
a number of subsequent clinical trials (table 2).  The lack of overt toxicity has been largely 
consistent in the literature, with one exception.  In 2016 cytotoxicity of salvinorin A was 
 28 
 
reported for the first time from an in vitro MTT-based cell viability assay utilizing N27, A549, 
Caco-2, HepG2, COS-7, and HEK-293 cell lines that was both dose-dependent (0.1, 1, 10, and 
50 μM) and time-dependent (12-60 hours) across all cell lines (Marinho et al., 2016).  
 
Table 2.  Clinical trials with salvinorin A. 
Route of 
Administration 
Dose 
range 
Number of 
participants 
Physiological Effects Reference 
Vaporization 
/inhalation 
200-500 
µg 
6 No negative effects reported. Siebert 1994 
Vaporization/ 
inhalation 
0.375-
21µg/kg 
4 
No significant change to heart rate 
or blood pressure. 
Johnson et 
al., 2011 
Sublingual 1-4 mg 8 
No effects, poor bioavailability by 
sublingual administration. 
Mendelson et 
al.,  2011 
Vaporization/ 
inhalation 
100-1,017 
µg/kg 
30 
No significant change to body 
temperature or systolic blood 
pressure. 
Addy et al., 
2012 
Vaporization/ 
inhalation 
0-12 mg 10 
No significant change to blood 
pressure, heart rate, or euphoria. 
Ranganathan 
et al., 2012 
Vaporization/ 
inhalation 
0.375-
21µg/kg 
8 
No significant change to blood 
pressure or heart rate.  No resting 
or kinetic tremors were observed. 
MacLean et 
al., 2013 
 
 
 Due to the high affinity and efficacy of salvinorin A at KOR a discriminative study was 
undertaken in rhesus monkeys (Macaca mulatta) (Butelman et al., 2004).  This study revealed 
that subcutaneous administration of salvinorin A (0.001-0.032 mg/kg, SC) produced drug 
discriminative effects in rhesus monkeys similar to the high-efficacy KOR agonist U-69,593.  It 
also demonstrated that KOR antagonist 5’-guanidinonaltrindole (GNTI) failed to antagonize the 
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salvinorin A effect — possibly indicating that salvinorin A may possess a unique binding pose 
within KOR distinct from that of classical opioids.  Further in vivo pharmacological assessment 
of salvinorin A (2 mg/kg, IV) in a mouse climbing model of motor coordination reported a 
significant, but short-lived (≤ 15 minutes, with peak effects within five minutes), incoordination 
similar to the U-69,593 KOR agonist control (Fantegrossi et al., 2005).  This study observed a 
reduction in motor-incoordination when salvinorin A groups were pretreated with nor-
binaltrophamine (nor-BNI; KOR antagonist).  More interestingly however, this reduction was 
not observed in the U-69,593 control group — once more bolstering the proposal that the binding 
properties of salvinorin A within KOR may be unique. 
 The assessed in vivo pharmacological activities that are modulated by salvinorin A 
continues to increase, this includes:  antiproliferative, antipruritic, anti-inflammatory, anti-
protozoal, gastrointestinal hypermotility, and neuroprotective effects in brain ischemia-models 
— amongst others (Aviello et al., 2011; Calzada et al.,2015; Lozama et al., 2011; Vasiljevik et 
al., 2014; Wang et al., 2005; Xin et al.,2016).  However, our focus will be towards modulatory 
effects of salvinorin A in models of antinociception, conditioned place aversion, and depression. 
 Pharmacological characterization of salvinorin A has demonstrated KOR-mediated 
antinociceptive activity in mice.  The first published report was in 2006 utilizing both chemo -
nociceptive and thermo-nociceptive assays (McCurdy et al., 2006).  This study used two thermo-
nociceptive models:  tail-flick and hotplate, both revealing dose- and time-dependent 
antinociceptive effects.  Specifically, that salvinorin A possesses a short duration of activity, 
peaking at ten minutes with a rapid return to baseline.  This pattern of activity was also observed 
in their chemo-nociceptive assay.  Subsequent studies corroborated this pattern of 
 30 
 
antinociceptive activity in mice, including the short duration of activity (Ansonoff et al., 2006; 
John et al., 2006). 
Based upon previously establish effects of KOR agonists (e.g. U-69,593) that promote 
aversive effects in place preference models, decrease drug reward effects through altered 
dopamine levels and effect decreased cocaine self-administration, corresponding  
pharmacological characterization was undertaken with salvinorin A as an atypical opioid (Chiara 
and Imperato, 1988; Devine et al., 1993; Donzanti et al., 1992; Heidbreder et al., 1993).  A 2005 
study by the Zhang group used high doses of salvinorin A (1-3 mg/kg, IP) and established that 
this treatment lowered dorsal striatum dopamine levels, measured in vivo in mice (C57BL/6J 
mice) via microdialysis over a three hour duration post-treatment, in the caudate nucleus and 
putamen.  Moreover, this salvinorin A mediated reduction of striatal dopamine was completely 
blocked by pretreatment with KOR antagonist nor-BNI.  They also reported that at this dose 
range salvinorin A induced both conditioned place aversion and decreased locomotor activity in 
the test mice.   They concluded that that the inhibitory effect on striatal dopamine levels by 
salvinorin A administration may contribute to the observed conditioned place aversion and 
lowered locomotor rates (Zhang et al., 2005).  This conditioned place aversion was subsequently 
demonstrated in a rat model using male Sprague-Dawley rats in 2014, notably at a lower dose 
range (0.3-1 mg/kg, IP) than the previously used mouse model (Sufka et al., 2014).    
However, a 2007 conditioned place preference study by Daniela Braida in zebrafish 
(Danio rerio) reported that at a significantly lower dose range of 0.2-0.5 μg/kg of salvinorin A 
promoted place preference in the associated drug-compartment.  The highest dose assessed (80 
μg/kg) in this study produced aversive effects in zebrafish (Braida  et al., 2007).  In 2008 the 
Braida group translated this conditioned place preference study to male Wistar rats and reported 
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a rewarding effect by salvinorin A at 0.1-40 μg/kg (SC) doses and an aversive effect at 160 
μg/kg (SC) (Braida et al., 2008).  They also utilized a non-competitive self-administration 
paradigm and observed rewarding effects at doses 0.1-0.5 μg/intracerebroventricular (ICV) 
infusion, but aversive effects at 1μg/infusion.  Additionally, they were able to antagonize the 
reward effect of salvinorin A, as expected, by pretreatment with KOR antagonist nor-BNI, but 
more interestingly with cannabinoid receptor type-1 (CB1) antagonist rimonabant.  However, 
subsequent work in 2010 by the Walentiny group utilizing radioligand binding affinity, 
[
35
S]GTP[γS] functional assessment, and calcium channel signaling revealed that this apparent 
cannabinoid mediated activity by salvinorin A was not by direct activation — which corresponds 
to earlier studies which reported no direct affinity/activation of cannabinoid receptors by 
salvinorin A (Chavkin et al. 2004; Roth et al., 2002; Walentiny et al., 2010).  
In 2001 it was observed that the overlapping distribution of KOR expression with 
dopamine transporters (DAT) in striatal axons was strategically located to potentially modulate 
dopamine uptake (Svingos et al., 2001).  This study presented the first ultrastructural data 
showing KOR localization and potential involvement in presynaptic regulation of dopamine.  
Further work supporting the involvement of KOR dopamine modulation in conditioned place 
aversion utilized conditional knock-out mice (DAT Cre-KOR KO) and determined that KOR 
expression on dopaminergic neurons was essential for KOR-mediated conditioned place aversion 
behavior (Chefer et al., 2013).  Based upon the previously observed effect of decreasing 
dopamine-levels and promotion of conditioned place aversion by salvinorin A it was proposed 
that the mechanism of this activity may be through DAT/KOR modulation (Kivell et al., 2014).   
Utilizing transfected EM4 cells the Kivell group in 2014 observed that salvinorin A only 
promoted DAT activation in DAT/KOR co-expressing cells via measured change of 4-(4-
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diethylaminostyryl)-N-methylpyridinium iodide (ASP
+ 
) substrate accumulation in the test cells, 
this accumulation was not observed in cells that only expressed DAT.  Additionally, this altered 
DAT function in DOR/KOR co-expressing cells was reversible with nor-BNI treatment.  They 
measured that this effect was differential between amine transporters as they observed a 
decreased rate of ASP
+ 
substrate accumulation with the serotonin transporter (SERT) and no 
alteration with the norepinephrine transporter (NET). 
Employing a surface biotinylation assay they reported that salvinorin A up-regulated 
DAT surface expression in DAT/KOR co-expressing EM4 cells and that this effect was linked to 
the extracellular signal regulated kinase-1/2 (ERK1/2) pathway as inhibition with PD98059 (an 
ERK1/2 inhibitor) blocked this up-regulated DAT surface expression.  Immunoblotting revealed 
that salvinorin A promoted increased phosphorylation of ERK1/2, but not P38 mitogen-activated 
protein kinase (P38 MAPK) signaling in their DAT/KOR co-expressing EM4 cells.  Inhibition of 
ERK1/2 by PD98059 prevented salvinorin A modulation of DAT ASP
+ 
accumulation, while 
inhibition of P38 MAPK by SB203580 (a P38 MAPK inhibitor) failed to alter salvinorin A DAT 
effects which may indicate an ERK1/2 dependent mechanism of action for the observed 
dopamine modulation by salvinorin A (Kivell et al., 2014).   
With the established trend of KOR agonist induced dysphoria and the dopamine 
modulation effects of salvinorin A it was posited that this may represent an approach towards 
altering addictive responses observed with drugs of abuse, such as cocaine (Chartoff et al., 
2008).  An initial study observed that in male Sprague-Dawley rats acute treatment with 
salvinorin A (2 mg/kg, IP) resulted in attenuation of locomotor stimulant effects from cocaine.  
Salvinorin A (0.3 mg/kg, IP) attenuation of locomotor stimulant effects from cocaine in Sprague-
Dawley rats was also observed by the Morani group in 2012, but they further reported that 
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salvinorin A treatment produced fewer adverse effects (such as sedation, aversion, and 
depression) as commonly seen with other KOR agonist (e.g. U-69,593) (Morani et al., 2012).  
Following this vein, use of a male Sprague-Dawley rat self-administration model found that 
salvinorin A treatments (0.3-1 mg/kg, IP) attenuated cocaine self-administration, and had no 
effect on operant response for sucrose reinforcement (Morani et al., 2009).  This work was 
subsequently translated to rhesus monkeys in 2014, where not only did salvinorin A attenuate 
cocaine self-administration, but MOR agonist remifentanil self-administration as well, in a dose-
dependent manner (Freeman et al., 2014). 
Lastly, for our specific pharmacological interest in salvinorin A there is the potential 
modulatory role in depression.  Numerous studies have indicated involvement of the opioid 
system, and KOR in particular, in a diverse array of critical behavioral states, including:  
addiction, anxiety, and depression (Al-Hasani and Bruchas, 2011; Lalanne et al., 2014; Ling et 
al., 2011).  Furthermore, there is an accumulated body of evidence demonstrating that KOR 
activation can produce depression-like effects both in model organisms and, more importantly, in 
humans (Carlezon et al., 2006; Ebner, et al., 2010; Lalanne et al., 2014; Pfeiffer et al., 1986).  In 
2006 it was reported that in forced swim tests (FST) and intracranial self-stimulation (ICSS) 
tests, both standard depression-like models, in male Sprague-Dawley rats that administration of 
salvinorin A (0.5-2.0 mg/kg, IP) would promote depression-like effects (Carlezon et al., 2006).  
This study also observed that salvinorin A decreased striatal dopamine levels, but not serotonin 
levels, within the nucleus accumbens — which is thought to play a critical role in reward 
response related to addiction, as well as, depression and anxiety (Bewernick et al., 2010; Lalanne 
et al., 2014; Olsen 2011). These results were corroborated in 2010 by the Ebner group also 
utilizing the ICSS model in male Sprague-Dawley rats and administering salvinorin A at two 
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doses 0.25 mg/kg and 2.0 mg/kg (IP), however they found only the high dose of 2.0 mg/kg 
promoted the depression-like effects (Ebner, et al., 2010).  They also reported a corresponding 
decrease in striatal dopamine levels within the nucleus accumbens.  
However, a 2009 study observed that salvinorin A (01-160.0 μg/kg, SC) produced 
anxiolytic-like effects in male Sprague-Dawley rats when assessed in using an elevated plus 
maze, anti-depressant-like effects in male Sprague-Dawley rats in a FST, and anti-depressant-
like effects in male Albino Swiss mice assessed utilizing a tail suspension test (TST) — effects 
which were antagonized by nor-BNI treatment (Braida et al., 2009).  Ultimately, these studies 
(Table 3) illustrate the pharmacological complexity observed in the study of salvinorin A:  not 
simply in various models/model organisms, but also with the range of observed effects that dose 
and route of administration potentiate.  Together this research demonstrates that additional 
pharmacological characterization of salvinorin A and elucidation of mechanisms of activity are 
needed. 
Table 3.  Summary of preclinical in vivo studies with salvinorin A. 
Model Organism Test Model Activity Dose 
Route of 
Administration 
Time-
Course 
Reference 
C57BL/6J mice CPP Aversive 
1.0-3.2 
mg/kg 
IP 30 min 
Zhang et 
al., 2005 
 
Male Swiss mice 
Tail-flick 
test 
Antinociceptive 
1.0-4.0 
mg/kg 
IP 20 min 
McCurdy 
et al., 
2006 
Male Swiss mice Hotplate Antinociceptive 
1.0 
mg/kg 
IP 10 min 
McCurdy 
et al., 
2006 
Male Swiss mice 
Acetic acid 
abdominal 
constriction 
assay 
Antinociceptive 
0.5-2.0 
mg/kg 
IP 15 min 
McCurdy 
et al., 
2006 
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Table 3.  Summary of preclinical in vivo studies with salvinorin A. (continued) 
Model Organism Test Model Activity Dose 
Route of 
Administration 
Time-
Course 
Reference 
C57BL6/Jx129S6 
mice 
Tail-flick test Antinociceptive 7.5 μg ICV 15 min 
Ansonoff 
et al., 
2006 
CD-1 mice Tail-flick test Antinociceptive 
13.9-
23.1 
nmol 
IT 10 min 
John et 
al., 2006 
Male Sprague-
Dawley rats 
FST 
Depressive-like 
effect 
0.25-2.0 
mg/kg 
IP 15 min 
Carlezon 
et al., 
2006 
Male Sprague-
Dawley rats 
ICSS Attenuates 
0.5-2.0 
mg/kg 
IP 1 hr 
Carlezon 
et al., 
2006 
Zebrafish CPP Rewarding 
0.2-0.5 
μg/kg 
Dissolved 15 min 
Braida  et 
al., 2007 
Zebrafish CPP Aversive 
80 
μg/kg  
Dissolved 15 min 
Braida  et 
al., 2007 
Wistar rats CPP Rewarding 
0.1-40.0 
μg/kg  
SC 30 min 
Braida et 
al., 2008 
Wistar rats CPP Aversive 
160.0 
μg/kg 
SC 30 min 
Braida et 
al., 2008 
Male Sprague-
Dawley rats 
Cocaine 
induced 
locomotor 
activity 
Attenuates 
2.0 
mg/kg 
IP 2 hr 
Chartoff 
et al., 
2008 
Male Sprague-
Dawley rats 
Cocaine 
induced 
locomotor 
activity 
Attenuates 
0.3 
mg/kg 
IP 1 hr 
Morani et 
al., 2009 
Male Sprague-
Dawley rats 
Cocaine self-
administration 
Attenuates 
0.3-1.0 
mg/kg 
IP 2 hr 
Morani et 
al., 2009 
Male Sprague-
Dawley rats 
FST 
Anti-
depressant-like 
effect 
0.1-
160.0 
μg/kg 
SC 15 min 
Braida et 
al., 2009 
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Table 3.  Summary of preclinical in vivo studies with salvinorin A. (continued) 
Model 
Organism 
Test Model Activity Dose 
Route of 
Administration 
Time-
Course 
Reference 
Male Sprague-
Dawley rats 
Elevated plus 
maze 
Anxiolytic-like 
effects 
0.1-160.0 
μg/kg 
SC 20 min 
Braida et 
al., 2009 
Male Sprague-
Dawley rats 
TST 
Anti-
depressant-like 
effect 
0.1-160.0 
μg/kg 
SC 6 min 
Braida et 
al., 2009 
Male Sprague-
Dawley rats 
ICSS Attenuates 2 mg/kg IP 3 hr 
Ebner, et 
al., 2010 
Male Sprague-
Dawley rats 
CPP Aversive 
0.3-1.0 
mg/kg 
IP 15 min 
Sufka et 
al., 2014 
Rhesus 
monkeys 
Cocaine self-
administration 
Attenuates 
0.1 
mg/kg/inj 
IV 
*Ten 
choice 
sessions 
Freeman 
et al., 
2014 
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CHAPTER 3:  Salvinorin Analogues 
In developing this pharmacological understanding of salvinorin A necessary work has 
been undertaken to explore the chemistry of this compound.  The first report of successful total 
synthesis of salvinorin A occurred in 2007 by David A. Evans, consisting of a 29 step reaction 
with an overall yield of 0.8% (Scheerer et al., 2007).  This was subsequently improved by 
Hisahiro Hagiwara in 2008, whose group achieved a reduction to 20 steps with a total yield 
improvement to 0.95% (Nozawa et al., 2008).  In 2009 the Hagiwara group reported a second-
generation synthesis scheme that further reduced the number of steps to 13 and increased the 
total yield to 2.8% (Hagiwara et al., 2009).  However, in terms of cost effectiveness, the current 
synthetic routes are still not competitive with the crude, but effective, isolation of salvinorin A 
from the host plant Salvia divinorum, which typically yield in excess of 3% (Munro and 
Rizzacasa, 2003; Sufka et al., 2014).  
In addition, there are a growing number of natural products that have been isolated from 
Salvia divinorum; however special interest has continued to be focused on those possessing 
neoclerodane diterpenoid structures.  To date there have been an additional nine salvinorin 
compounds isolated, designated salvinorin A-J (Figure 20).  However, with the exception of  
salvinorin B, most have yet to be pharmacologically characterized to any significant degree (for 
further information see references in Table 4). 
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Figure 20.  Natural salvinorin analogues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.  Natural salvinorin analogues 
Natural Product Reference 
Salvinorin A 
Grundman et al., 2007; Hanson, 2010; Ortega et al., 1982; 
Shirota et al., 2006; Valdes et al., 1984 
Salvinorin B 
Grundman et al., 2007; Shirota et al., 2006; Valdes et al., 
1984 
Salvinorin C Grundman et al., 2007; Shirota et al., 2006 
Salvinorin D 
Bigham et al., 2003; Munro and Rizzacasa, 2003; Shirota et 
al., 2006 
Salvinorin E Munro and Rizzacasa, 2003; Shirota et al., 2006 
Salvinorin F Munro and Rizzacasa, 2003; Shirota et al., 2006 
Salvinorin G Shirota et al., 2006 
Salvinorin H Shirota et al., 2006 
Salvinorin I Shirota et al., 2006 
Salvinorin J Kutrzeba et al.,2009 
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 Beyond these naturally occurring analogues, in exploring the structure-activity 
relationship of salvinorin A there have been more than 300 analogues synthesized (for an 
excellent review up to 2011 see:  Cunningham et al., 2011).  The majority of these analogues 
have only been utilized as molecular probes targeting KOR, strictly being assessed for KOR 
binding affinity.  However, increasingly there has been a wider application of salvinoin A-based 
molecular probes being used to characterize DOR and MOR via binding affinities, as well as, 
measures of functional activity — with an increasing number progressing to applications within 
in vivo pharmacological models (Aviello et al., 2011; Calzada et al.,2015; Cunningham et al., 
2011; Prisinzano and Rothman, 2008; Salaga et al., 2014; Vasiljevik et al., 2014; Wang et al., 
2005; White et al., 2015; Xin et al.,2016; Yan et al., 2009).  Nevertheless, the majority of 
research has focused on establishing a structure-activity relationship of the salvinorin A structure 
at KOR.   
Such research has revealed that the C(2)-position of salvinorin A represents a critical 
pharmacophore feature for interaction at KOR.  This is best exemplified by the hydrolysis of 
Figure 21.  Key pharmacophore 
features of salvinorin A.  Keasling 
and Zjawiony, 2016.  Reprinted 
with permission.   
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salvinorin A at the C(2)-position into the KOR-inactive natural product salvinorin B (Chavkin et 
al., 2004).  The general pattern amongst the current molecular probes indicates that analogues 
whose functional C(2)-position substitutions are able to mimic the carbonyl oxygen 
characteristics of the lead, salvinorin A, exhibit the highest binding affinities toward KOR 
(Cunningham et al., 2011).  Exploration of other prominent pharmacophore features (Figure 21) 
of the salvinorin A structure have generally shown that structural modifications to the C(1)-
position [ketone], C(4)-position [carbomethoxy], C(12)-position [furan], and the C(17)-position 
[lactone] result in a reduced KOR binding affinity, with only minor alterations at these positions 
being tolerated (Cunningham et al., 2011; Lozama  et al., 2011; Riley et al., 2014).   
However, in 2005 while exploring the C(2)-position of salvinorin A via structural 
modification the Prisinzano group reported one analogue exhibiting a surprising pharmacological 
effect (Harding et al., 2005).  The addition of an aromatic substitution at the C(22)-position 
(Figure 22), through the introduction of a benzoyl group at C(2), reduced the subsequent binding 
affinity towards KOR 47-fold (Ki of 90 nM) and reduced the functional activity 33-fold (EC50 of 
1320 nM), as assessed utilizing a [
35
S] GTP[γS] binding assay (Table 5).  However, this isn’t 
surprising as most salvinorin A analogues exhibit a decreased or abolished KOR binding affinity.  
What was surprising was that this substitution induced a MOR binding affinity (Ki of 12 nM) 
and functional activity (EC50 of 500 nM), with the authors reporting this to be the first salvinorin 
A-based agonist exhibiting high binding affinity towards MOR (Harding et al., 2005). 
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Due to this novel activity, additional characterization was pursued in 2007, by which time 
the compound had been named Herkinorin (Groer et al., 2007).  This study revealed that 
Herkinorin promoted phosphorylation of MAP kinases ERK1/2 in a dose-dependent manner, 
similar to salvinorin A (see Chapter 2), but mediated through MOR and was able to be 
antagonized by treatment with naloxone.  They also reported that this ERK1/2 activation was 
independent from β-arrestin-2 signaling and that Herkinorin does not promote the MOR 
recruitment of β-arrestin-2 (Figure 23).  This is of interest as there is a growing body of research 
indicating β-arrestin-2 involvement in MOR regulation and that β-arrestin-2-KO mice exhibit 
reduced opioid tolerance development, improved opioid-induced antinociception, and abolished 
both respiratory suppression and morphine-induced constipation (Bohn et al., 1999; Bohn et al., 
2002; Przewlocka, et al., 2002; Raehal et al., 2005).  Furthermore, this study showed that 
Herkinorin did not promote MOR internalization (Figure 24).  This is of interest as GPCR-
 
 
Figure 22.  Structure of Herkinorin. 
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Figure 24.  MOR agonist-mediated internalization.  Shows effect of agonist 
treatment on MOR-YFP in HEK-293 cells.  Groer et al., 2007.  Reprinted with 
permission. 
internalization has been associated with opioid-induced addiction and posited as a means of 
receptor regulation (Bohn et al., 2004; Connor et al., 2004; Gainetdinov et al. 2004).   
 
 
  
 
 
 
 
 
 
 
Subsequent pharmacological characterization of Herkinorin (1-10 mg/kg, SC) in male 
Sprague-Dawley rats utilizing a formalin chemo-nociceptive model revealed dose-dependent 
antinociception in both phase one (neurogenic pain caused by direct stimulation of the 
nociceptors) and phase two (inflammatory pain caused by release of inflammatory mediators), 
 
Figure 23.  Herkinorin effect on β-arrestin-2 recruitment.  Shows MOR mediated 
translocation of β-arrestin-2-GFP by agonist treatments:  DAMGO (1 μM) and 
Herkinorin (2 μM).  Groer et al., 2007.  Reprinted with permission. 
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Figure 25.  C(22)-position naphthalene and thiophene analogues of salvinorin A. 
with these antinociceptive effects being antagonized by naloxone pretreatment (Lamb et al., 
2012).  Interestingly, they showed that contralateral administration failed to promote similar 
antinociceptive effects — possibly indicating a peripheral restriction of Herkinorin to the site of 
administration.  They also utilized a tolerance development model to assess the effects of chronic 
administration of Herkinorin (10 mg/kg, SC) as measured using the previous formalin assay and 
found that it was still effective in both phases, potentially indicating a decreased tolerance 
liability for this pharmacophore (see Table 5 for in vivo summary of Herkinorin).   
Following this vein, an additional series of salvinorin A-based molecular probes were 
generated where C(22)-position aromatic substitutions were explored (Tidgewell et al., 2008).  
Of particular interest were the bicyclic addition of naphthalene-1 (Figure 25-1), naphthalene-2 
(Figure 25-2) and the heteroaromatic addition of thiophene-2 (Figure 25-3) and thiophene-3 
(Figure 25-4).  While the steric bulk of the naphthalene addition was tolerated, the subtle ester-
linkage shift from the substituent 1-postion to the substituent 2-position resulted in a preferential 
binding affinity towards KOR or MOR, respectively (Table 5), with significantly reduced 
binding affinity at other opioid subtypes.  In the heteroaromatic thiophene analogues the 
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KOR/MOR binding affinity is far more balanced, without clear preferential affinity towards a 
single opioid receptor subtype.  However, the preliminary activity is comparable to Herkinorin 
(Table 5). 
 Together this data potentially indicates that the steric bulk of bicyclic C(22)-substitutions 
on salvinorin A would not only be tolerated, but also that a subtle 1-/2-substituent-linkage 
alteration may provide an approach for developing opioid receptor subtype-preferential 
molecular probes.  Additionally, the C(22)-heteroaromatic substitutions appears to be well 
tolerated and from the preliminary in vitro data (Table 5) may yield analogues with increased 
functional activity at KOR, as compared to the Herkinorin lead.  
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Table 5.  In vitro data summary of aromatic analogues of salvinorin A. 
Analogue Figure 
Binding affinity 
Ki ± SD, nM 
Functional Activity 
[
35S]GTP[γS] binding, 
EC50 ± SD, nM 
Reference 
  DOR KOR MOR KOR MOR  
Herkinorin 22 
1170 
±60 
90  
±2 
12 
±1 
1,320 
±150 
500 
±140 
Tidgewell 
et al., 
2008 
naphthalene-1 25-1 >10,000 
410 
±40 
>10,000 — — 
Tidgewell 
et al., 
2008 
naphthalene-2 25-2 >10,000 
5,490 
±640 
180  
±20 
— — 
Tidgewell 
et al., 
2008 
thiophene-2 25-3 
1,380  
±130 
260 
±20 
10 
±2 
— 
1,150 
±250 
Tidgewell 
et al., 
2008 
thiophene-3 25-4 
690 
±30 
80 
±3 
10 
±1 
840 
±210 
690 
±60 
Tidgewell 
et al., 
2008 
benzofuran-2 
(P-3l) 
26 
580 
±30 
70 
±2 
10 
±1 
1,120 
±170 
1,680 
±250 
Tidgewell 
et al., 
2008 
PR-38 27 
700 
±101 
9 
±2 
52 
±9 
— — 
Polepally 
et al., 
2014 
— Indicates not assessed. 
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 These results supported further exploration as to the effect that incorporation of a fused-
heteroaromatic substituent would have at the salvinorin A C(22)-position.  This led to the 
generation of a single analogue incorporating benzofuran-2 at this position (P-3l; Figure 26) 
(Tidgewell et al., 2008).  Compared to the previous aromatic substitutions, including that of the 
Herkinorin lead, in vitro pharmacological assessment of P-3l revealed an increased binding 
affinity by this fused-heteroaromatic analogue at all three opioid receptor subtypes (Table 5).  
Additionally, when assessed utilizing a [
35
S] GTP[γS] binding assay, the P-3l analogue exhibited 
a functional activity at KOR that was comparable to the Herkinorin lead and at MOR that was 
comparable to the thiophene-2 analogue (Table 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26.  Structure of 2-O-salvinorin B benzofuran-2-
carboxylate (P-3l). 
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 Separately, in 2014 while exploring the effect that incorporation of Michael acceptor-type 
linkers at the C(2)-position of salvinorin A has on resulting aromatic analogues, the Zjawiony 
group reported the generation of a cinnamoyl analogue designated as PR-38 (Figure 27) 
(Polepally et al.,2014).  This salvinorin A analogue displayed a preferential binding affinity for 
KOR (Ki of 9 nM) and, interestingly, retained MOR binding affinity (Ki of 52 nM) (Table 5).  
The high binding dual-affinity at KOR/MOR observed with the PR-38 compound encouraged 
further in vivo pharmacological assessment. 
  
 
 
 
 
 
 
 
 
 
 
 
 Utilizing a male BALB/c mouse model of irritable bowel syndrome (IBS) PR-38 (10-20 
mg/kg, IP) was found to inhibit gastrointestinal hypermotility (Table 6) and colonic bead 
expulsion (Salaga et al., 2014).  Additionally, PR-38 (10 mg/kg, IP) was found to produce 
antinociceptive effects in a male BALB/c mouse chemo-nociceptive model (acetic acid-induced 
 
 
Figure 27.  Structure of 2-O-cinnamoylsalvinorin B (PR-38). 
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abdominal writhing assay).  Of particular interest is that this study utilized, in addition to 
intraperitoneal administration, oral administration — a route of administration rarely examined, 
due to the in-activity of the salvinroin A lead, and found PR-38 to be orally active.  A subsequent 
study employing a Swiss-Webster mouse pruritus model reported that PR-38 (10-20 mg/kg) 
promoted antipruritic activity when administered both subcutaneously and orally (Salaga et al.,  
2015). 
Computational modeling was undertaken to examine the potential ligand-receptor 
interactions that distinguish PR-38 from the salvinorin A lead (Polepally et al.,2014).   Utilizing 
the then available ‘inactive’ (i.e. antagonist co-crystallized) crystal structure of KOR complexed 
with JDTic (PDB: 4DJH) the orthosteric binding site for the salvinorin tricyclic core was defined 
utilizing residues:  Asp-138, Gln-115, Thr-111, Val-108, Val-118, Val-134, and Val-135 — 
these residues were supported by prior mutagenesis studies (Vardy et al., 2013; Wu et al., 2012).  
This oriented the salvinorin tricyclic core towards TM2, with the C(2)-position interacting with a 
binding pocket delineated with Asp-138, Met-142, and Tyr-139.  What this model showed was 
that the olefinic chain of the Michael acceptor-type linker is able to effectively fill a Asp-138, 
Met-142, and Tyr-139 delineated pocket and allow the aromatic substituent to extend beyond 
into a hydrophobic pocket bounded by TM3 and TM6, displaying key interactions with Met-142 
and Ile-294.  The researchers concluded that their model indicated that the C(2)-olefin portion of 
PR-38 serves as hydrophobic linker and likely facilitates the engagement of the aromatic 
substituent with a critical hydrophobic region within the receptor.   
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Table 6.  In vivo activity summary of aromatic analogues of salvinorin A. 
Analogue 
Model 
Organism 
Test Model Activity Dose 
Route of 
Administration 
Time-
Course 
Reference 
Herkinorin 
Male 
Sprague-
Dawley 
rats 
Formalin assay 
— phase 1 
(neurogenic 
pain) 
Antinociceptive 
1-10 
mg/kg 
SC 1 hour 
Lamb et 
al., 2012 
Herkinorin 
Male 
Sprague-
Dawley 
rats 
Formalin assay 
— phase 2 
(inflammatory 
pain) 
Antinociceptive 
10 
mg/kg 
SC 1 hour 
Lamb et 
al., 2012 
Herkinorin 
Male 
Sprague-
Dawley 
rats 
Tolerance 
development 
No tolerance 
development 
10 
mg/kg 
SC 5 day 
Lamb et 
al., 2012 
PR-38 
Male 
BALB/c 
mice 
Gastrointestinal 
hypermotility 
Reduced 
motility 
10-20 
mg/kg 
IP and P.O. 
20 
min 
Salaga et 
al., 2014 
PR-38 
Male 
BALB/c 
mice 
Colonic bead 
expulsion test 
Inhibited 
colonic 
expulsion 
10-20 
mg/kg 
IP 
45 
min 
Salaga et 
al., 2014 
PR-38 
Male 
BALB/c 
mice 
Acetic acid-
induced 
abdominal 
writhing assay 
Antinociceptive 
10 
mg/kg 
IP 5 min 
Salaga et 
al., 2014 
PR-38 
Swiss-
Webster 
mice 
Pruritus model Antipruritic 
10-20 
mg/kg 
SC 
120 
min 
Salaga et 
al., 2015 
PR-38 
Swiss-
Webster 
mice 
Pruritus model Antipruritic 
10 
mg/kg 
P.O. 
120 
min 
Salaga et 
al., 2015 
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CHAPTER 4:  Rationale, Specific Aims, and Expected Outcomes 
 The field of salvinorin chemistry represents novel and emerging field of opioid research.  
The novelty of this field is derived from the lead pharmacophore:  salvinorin A — a 
pharmacologically unique compound which represents the first known  non-nitrogenous KOR 
subtype-selective opioid receptor agonist, exhibits a comparatively safe physiological profile 
with no reports of toxicological effects in clinical trials, and, most importantly, has a steadily 
growing body of literature indicating potentially useful clinical applications (e.g. antinociceptive, 
anti-addictive, antipruritic, neuroprotective, etc.) (Aviello et al., 2011; Mowry et al., 2003; Roth 
et al.¸ 2002; Wang et al., 2005; Xin et al.,2016).  The emerging status of this field of research 
entails both the relatively recent beginnings, arguably founded in 2002 with the identification of 
the KOR target for salvinorin A by the Roth group, and subsequently with the growing body of 
salvinorin analogues, exemplified by the recent development of aromatic analogues 
(Cunningham et al., 2011; Groer et al., 2007; Harding et al., 2005; Polepally et al.,2014; Roth et 
al.¸ 2002).   
 The development of salvinorin A aromatic analogues is of particular interest due to the 
resulting range of pharmacological activity that has been reported.  The 2005 report 
incorporating a benzoyl substituent at the C(2)-position resulted in the first report of a non-
nitrogenous high-binding affinity agonist at MOR — a compound subsequently named 
Herkinorin (Groer et al., 2007; Harding et al., 2005).  Ensuing pharmacological characterization 
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of this aromatic salvinorin A analogue revealed that it did not promote β-arrestin-2 recruitment, 
receptor internalization, or tolerance development — all undesirable activities commonly seen 
with classical opioids (Groer et al., 2007; Lamb et al., 2012).   
 Subsequent incorporation of a cinnamoyl moiety at the C(2)-position of salvinorin A, a 
compound designated as PR-38, resulted in a molecular probe with high-binding affinity towards 
KOR/MOR (Table 5).  More interestingly, however, PR-38 was uniquely found to be orally 
active and promote both antinociceptive and antipruritic activities (Table 6) (Polepally et 
al.,2014; Salaga et al., 2014; Salaga et al., 2015).  Along these lines, incorporation of 
naphthalene and thiophene substituents at the C(22)-position of salvinorin A, which conserve the 
conjugation observed with the Michael acceptor-type linker found in PR-38, resulted in fused-
aromatic and heteroaromatic analogues that display high-binding affinity, with subtype 
selectivity observed in the case of the naphthalene analogues (Table 5).  Lastly, represented by a 
single molecular probe, the incorporation of a benzofuran-2 moiety (P-3l) at the salvinorin A 
C(22)-position represents a potentially interesting line of research that has yet to be expanded. 
 Preliminary in vitro assessment of P-3l (Table 5) reveals that this analogue possesses 
high-binding affinity, preferential for MOR/KOR, and functional activity as well (as assessed via  
[
35
S] GTP[γS] binding).  Structurally, it also retains key features of the preceding aromatic 
analogues:  it is a fused-heteroaromatic substituent that merges the fused-bicyclic feature of the 
naphthalene analogues, the heteroaromaticity of the thiophene analogues, and the aromatic-
conjugated system observed with PR-38.  This structural template affords a unique opportunity 
to explore the effect of bioisosteric replacement [e.g. C/N/O/S] at the substituent 1-position and 
the effect that substituent 2-/3-linkage with salvinorin A has on the ensuing pharmacology to 
better characterize the opioid system.  Due to the importance of this system, this series of 
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molecular probes will help address the continuing need for new research tools capable of 
ascertaining potential three-dimensional ligand binding requirements, functional activities, and 
pharmacological consequences. 
Specific Aims: 
AIM 1.  Synthesis of C(22)-fused-heteroaromatic salvinorin A analogues. 
AIM 2.  In vitro evaluation of analogues at the opioid receptors. 
2a. Evaluation of ligand binding affinity at δ (Delta), κ (Kappa), and μ (Mu) opioid 
receptors utilizing a competitive radioligand binding assay. 
2b. Evaluation of ligand induced functional activity at opioid receptors measured by 
[
35S]GTP[γS] binding assay. 
AIM 3.  In vivo antinociceptive evaluation of analogues in mouse models 
3a. Acetic Acid-induced Abdominal Writhing Assay 
3b. Formalin Assay 
3b. Opioid Antagonism Assay 
3c. Hot Plate Assay 
 
Expected Outcomes: 
 Design of a fused-heteroaromatic series of dual-affinity KOR/MOR salvinorin A-based 
molecular probes. 
 Elucidation of structural motifs by which KOR/MOR affinity may preferentially be induced. 
 Determination of the pharmacological relevance of designated analogues towards mouse 
models of antinociceptive activity. 
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Scheme 1. General synthesis procedure.  Reagents and conditions:  (A) Na2CO3, anhyd. 
MeOH, stirred, r.t. 8 hr.; (B) appropriate carboxylic acid, DCC, DMAP, anhyd. CH2Cl2, 
Ar atmo., stirred, r.t. 12 hr. 
 
 
 
 
 
CHAPTER 5:  Experimental Methods 
Chemistry 
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General Synthesis Procedure 
All reagents were purchased from commercial suppliers and, except where indicated, 
were used without additional purification.   
 The general procedure used to deacetylate salvinorin A to salvinorin B was as follows:  a 
mixture of salvinorin A (3.5 g, 8.0 mmol, 1 equivalents) and sodium carbonate (3.4 g, 32.2 
mmol, 4 equivalents) in absolute methanol (150 mL) was equipped with a stir bar and stirred at 
room temperature overnight.  The methanol was removed under reduced pressure and the residue 
solubilized in dichloromethane (DCM, 500 mL).  This solution was successively washed with 
2N hydrochloric acid (HCl, 100 mL), sodium chloride solution (NaCl, 100 mL), and dried with 
sodium sulfate (Na2SO4).  The DCM was removed under vacuum and the resulting solid 
resuspended in methanol, filtered and dried to yield salvinorin B (Tidgewell et al. 2004). 
The general procedure used to generate this series of analogues outlined  (Scheme 1) was as 
follows:  a solution of salvinorin B (0.10 g, 0.26 mmol, 1 equivalents), appropriate carboxylic 
acid (0.51 mmol, 2-3 equivalents), 1,4-dicyclohexylcarbodimide (DCC; 0.132 g, 0.61 mmol, 2 
equivalents), and catalytic amount of 4-(dimethylamino)pyridine (DMAP) were added to a round 
bottom flask equipped with stir bar and then flushed with Argon, before being sealed under 
Argon atmosphere.  To the reaction vessel was added anhydrous DCM (5 mL) this was placed in 
an ice bath (0°C) and while stirring allowed to reach room temperature overnight.  After 
checking with TLC (short/long UV and vanillin stain; Sorbent Technologies, Atlanta, GA; Silica 
G TLC Plates w/UV254, 200 μm thickness, polyester backed) to ensure completion of reaction, 
material was partitioned between deionized water and the organic DCM layer dried under 
reduced pressure to yield the crude reaction material ready for chromatographic purification 
(Polepally et al. 2014; Tidgewell et al. 2008). 
 55 
 
 
Chromatography 
The general procedure used to purify analogues in this series was as follows:  the crude 
reaction material was first processed via vacuum liquid chromatography (VLC) across silica gel 
(Sorbent Technologies, Atlanta, GA; Silica Gel, 200g, Porosity:  60 Å, Particle Size:  230 x 400 
mesh) using a 10% solvent gradient from 100% n-hexane to 100% ethyl acetate.  The collected 
fractions were checked with TLC (UV and vanillin stain) and combined based on characteristic 
staining profile.  Combined fractions were then dried under vacuum via rotary evaporator and 
loaded on onto a Sephadex LH-20 gravity column (GE Healthcare Life Sciences, Chicago, IL; 
100 g) equilibrated in chloroform:methanol (1:1).  The collected fractions were checked with 
TLC (UV and vanillin stain) and combined based on profile.  Combined fractions were then 
dried under vacuum via rotary evaporator and loaded on onto a C18 reverse phase silica gel 
column (Acros Organics, NJ; C18  Silica Gel, 200g, 23%C, ca. 1.2 mmol/g, particle size: 40-63 
μm) that was equilibrated water:methanol (90:10).  This column was processed using a 5% VLC 
solvent gradient to 100% methanol, with the column stripped with methanol:ethyl acetate (95:5) 
to yield the target analogue.  This general chromatography procedure was validated via a Waters 
2487 Analytical HPLC utilizing Phenomenex Hydro-RP C18 column (Phenomenex; Torrance, 
CA;10x250mm, Synergi Hydro-RP 10um, 80 Å) and a YMC-Polyamine II column (YMC 
America, Inc.; Allentown, PA;150x10mm) using an elution rate of 3 ml/minute.  We processed 
the analogue utilizing an isocratic acetonitrile:water (70:30) solvent system first across the C18 
column (Figure 28) and then the polyamine column (Figure 29).  This general chromatography 
procedure was found to result in material of ≥95% purity by UV detection and a percent yield 
typically between 30-38% for the resulting analogues. 
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Structural Elucidation 
Nuclear Magnetic Resonance (NMR) spectra were obtained for both carbon (
13
C) and proton 
(
1
H) of all compounds measured using a Bruker Avance NMR spectrometer (400 UltraShield, 54 
mm standard magnet bore; Billerica, MA)  equipped with a 3mm probe with spectra recorded at 
Phenomenex Hydro-RP C18 column 
 
 
Figure 28.  Representative C18-HPLC-UV chromatogram. 
YMC-Polyamine II column 
 
Figure 29.  Representative NH2 -HPLC-UV chromatogram. 
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101 MHz and 400 MHz, respectively (Appendices A-C).  All samples were analyzed using 
deuterated chloroform as the solvent.  High-resolution mass spectrometric (HRMS) data was 
obtained employing a Bruker MicroTOF-ESI Mass Spectrometer (Billerica, MA) via direct 
injection with samples (1 mg/ml) solubilized in methanol. 
 
Pharmacological Characterization 
In Vitro Methods 
Opioid Receptor Binding Affinity 
Preliminary and secondary binding affinities were determined utilizing established 
competitive radioligand binding assays.  Briefly, we utilized stably transfected HEK-293 cells 
expressing human opioid receptor subtypes DOR, KOR, and MOR.  Stably transfected cell lines 
were maintained on Dulbecco’s Modified Eagle Medium (DMEM) nutrient media supplemented 
with fetal bovine serum (10%), hygromycin B (300 mg/mL), L-glutamine (2mM), and penicillin-
stryptomycin (0.5%) under a 5% atmosphere of carbon dioxide maintained at a temperature of 
37°C.  Membranes were prepared by scraping cells in a Tris-HCl buffer, followed by sonication 
facilitated homogenization and centrifugation (Leon et al.,2013; Polepally et al., 2014). 
In the preliminary binding assay the new analogues were assessed at 10 µM test 
concentrations with competitive incubation with [
3
H]-Enkephalin, [
3
H]-U‑69,593, or [3H]-
DAMGO for DOR, KOR, or MOR, respectively.  For controls, unlabeled DPDPE, nor-
Binaltorphimine, and DAMGO were used, once more for DOR, KOR, and MOR, respectively.  
After termination of the incubation cycle and multi-well washing, microplate scintillation values 
were determined using a TopCount NXT analyzer (Leon et al.,2013).  This first assay was used 
to calculate percent inhibition of the analogue to see if it met the 70% threshold to proceed to 
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secondary binding affinity evaluation.  Analogues meeting the 70% threshold were subsequently 
evaluated in the secondary bind affinity assay that utilized a 12-step serial dilution from 100 μM 
to 0.5 nM to calculate the equilibrium dissociation constant (Ki).  Analogues possessing a Ki 
≤300 nM were evaluated for functional activity utilizing a [35S]GTP[γS] binding assay. 
 
Opioid Receptor Functional Activity 
Methods similar to those in competitive radioligand binding assays functional assays 
were used for the [
35S]GTP[γS] binding assay.  Utilizing [35S]GTP[γS] as a measurable 
radioligand of GTP we measured the exchange of GDP at the inactive G-protein-coupled 
receptor (DOR, KOR, or MOR) for [
35S]GTP[γS] as a measure of receptor activation (i.e. 
functional activity) by ligands possessing a Ki ≤300 nM binding affinity in the secondary 
competitive radioligand binding assays.  As before, controls consisted of nor-Binaltorphimine 
and DAMGO for KOR and MOR, respectively and were assessed via serial dilution to calculate 
a dose response curve to determine analogue effect (i.e. full agonist, partial agonist, etc.) and to 
determine effective concentrations (EC50).  All in vitro assays were performed in triplicate (Leon 
et al.,2013). 
 
In Vivo Methods 
Test animals 
Test animals used in the following in vivo assays were male Swiss Webster mice (adults, 
21-24g), obtained from Harlan Laboratories.  Mice received water and food ad lib, while housed 
in groups of five.  Housing facilities were maintained on a lighting schedule of 12 hours (0600 to 
1800). 
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I.  Antinociceptive Related Assays 
Acetic Acid-induced Abdominal Writhing Test 
Groups of mice (n = 10) were treated by gavage (P.O.) with vehicle (10% DMSO, 10 
ml/kg, vehicle control), test analogue (1, 3, 10 mg/kg, P.O.), indomethacin 20 mg/kg or 
morphine 10 mg/kg (positive control for antinociceptive activity), 60 minutes before the 
administration of acetic acid solution (0.6% v/v; 10 ml/kg, IP) (Koster et al., 1959). The number 
of writhing movements produced in each group in the 30 minute test period was counted and the 
results were expressed as mean ± SEM as percentage of control group. A significant reduction in 
the number of writhing movements was considered to be a positive antinociceptive response. 
Formalin Assay 
The experimental groups of mice (n = 7) were treated by gavage (P.O.) with vehicle 
(10% DMSO, 10 mL/kg, vehicle control), test analogue (1, 3, 10 mg/kg, P.O.), indomethacin 20 
mg/kg (positive control for antinociceptive activity in the second phase), 60 minutes before, or 
subcutaneously (SC) with morphine 10 mg/kg (positive control for antinociceptive activity in the 
first and second phases), 30 minutes before the administration of formalin (20 μl, 3% v/v) in the 
right hind paw (Melo et al., 2005). After the formalin phlogistic agent injection, the mice were 
placed into an acrylic test box with a mirror located under the box to enable observation of the 
formalin-injected paw for 30 minutes.  Assessment of pain reaction time (i.e. time until paw 
licking behavior) was observed for two periods:   0 to 5 minutes — the first phase (neurogenic 
pain caused by direct stimulation of the nociceptors) and from 15 to 30 minutes — the second 
phase (inflammatory pain caused by release of inflammatory mediators) (Hunskaar et al., 1985).  
Results were expressed as mean ± SEM, in seconds. 
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Opioid Antagonism Assay  
To examine the involvement of opioids receptors in the observed antinociceptive activity 
in the formalin-induced pain assay.  The experimental group of mice (n = 7) were pretreated with  
saline (0.9 %, 10 ml/kg, IP, negative control) or naloxone 3 mg/kg, IP, opioid antagonist).  After 
15 minutes the mice were treated with vehicle (20 % DMSO, 10 ml/kg, P.O., vehicle control), 
test compound (10 mg/kg, P.O.) or morphine (10 mg/kg, P.O., positive control/opioid agonist).  
Sixty-minutes after oral administration, or 30 minutes after subcutaneous administration, the 
mice were administrated formalin (20 μl, 3 % v/v) in the right hind paw. The pain reaction time 
(time until paw licking behavior) was observed in the first phase (neurogenic pain) of formalin 
assay (Hunskaar et al., 1985). 
 
Hot Plate Assay 
The hot plate test was performed as previously described by Woolfe and MacDonald 
(1944).  The latency (in seconds) to reaction to the thermal stimulus, expressed by lifting of the 
hind paws accompanied by licking or flinch was measured using  hot plate (Insight®, Ribeirão 
Preto, São Paulo, Brazil) set at 55.5 ± 0.5 °C.  The mice were divided into four experimental 
groups (n = 8): vehicle (10% DMSO, 10 ml/kg, P.O.), test analogue (1, 3, 10 mg/kg, P.O.) or 
morphine (5 mg/kg, P.O., positive control for antinociceptive activity). The latency baseline was 
measured 30 minutes before of the treatments (time -30) and immediately after of the treatments 
(time 0) for each animal. After treatment, the latency to pain reaction was measured at 30, 60, 90, 
120, 150 and 180 minutes. A cut-off of 20 seconds was used to prevent the possibility of harm to 
the test animals.  Results were expressed as means ± SEM, in seconds, at the assessed times. 
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II.  Antidepressant Related Assays 
Forced Swim Test 
Test mice (n = 10) were evaluated by a forced swin test (FST)  after oral administration 
of vehicle (10% DMSO, 10 mL/kg, P.O.), test analogue (1, 3, 10 mg/kg, P.O.) or imipramine (15 
mg/kg, P.O.) (Fajemiroye et al., 2014; Porsolt et al., 1977).  Treated mice were placed 
individually in a cylindrical container of 18 cm diameter filled with water to the height of 30 cm 
in height, total volume of 7.6 L, at 24 ± 2°C.  Video from six-minute test sessions was recorded 
with the swimming and immobility time measured for statistical analysis.   
Tail Suspension Test 
A modified version of tail suspension test (TST) was employed with test mice (n = 10) 
administered oral treatment of either vehicle (10% DMSO, 10 mL/kg, P.O.), test analouge (1, 3, 
10 mg/kg, P.O.), or imipramine (15 mg/kg, P.O.) (Steru et al., 1985).  Treated mice were 
suspended using adhesive tape placed two centimers from the tip of the tail one hour after 
administartions of selected treatment.  Video from six-minute test sessions was recorded and the 
immobility time scored and analysed. 
 
 
III. Anxiolytic Related Assay  
Open Field Test 
A circular open field arena with base area 62 cm
2
 and eight equal sectorial-divisions enclosed 
with a 50 cm high wall was used to evaluate exploratory activity of the mice (Fajemiroye et al., 
2015; Fajemiroye et al., 2014).  Test mice (n = 10) were treated via oral administration either 
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vehicle (10% DMSO, 10 mL/kg, P.O.), test analogue (1, 3 or 10 mg/kg, P.O.), diazepam (5 
mg/kg, P.O.) one hour prior to the test session (five-minute duration) in the open field.  
Diazepam was used as a positive control in this model as this dose reliably induced anxiolytic-
like effects.  Video from five-minute test sessions was recorded and the exploratory activities 
scored and analysed. 
 
Computational Modeling 
Model Design 
We utilized the active-state agonist-bound μ-opioid receptor (MOR) X-ray crystal 
structure (PDB ID: 5C1M) published in late 2015 to develop an in silico homology model of the 
κ-opioid receptor (KOR) in its active state (Huang et al., 2015; Vardy et al., 2013).  The full 
sequence of human KOR was downloaded from the Uniprot website 
(http://www.uniprot.org/uniprot/P41145) and used to define key residue difference between 
KOR and MOR.   We utilized chain A of the 5C1M crystal structure, in which MOR is bound to 
the morphinan agonist BU72 as a template for generating multiple homology models. Alignment 
of the KOR and MOR sequences using ClustalW revealed that KOR and 5C1M possessed a 67% 
sequence identity and 81% sequence similarity after alignment (Figure 30).  Additionally, a 
critical disulfide bridge located in the extracellular-loop 2 of KOR between Cys-131 and Cys-
210 (Cys-140 and Cys-217 in MOR) was included in the model generation (Polepally et al., 
2014).  We generated ten preliminary models using the knowledge-based method implemented 
in 2016 Schrödinger suite.  Loop regions of these ten models were refined using the Prime 
module implemented in the Schrödinger suite and the quality of the protein structure models 
were assessed by Ramachandran plotting.  This analysis revealed that only one model expressed 
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all amino acids in the favored/allowed regions as defined in the Ramachandran plot (Figure 31) 
— therefore this was the model utilized for subsequent optimization (Schrödinger, 2017).  
The crystal structure of active state MOR obtained from the Protein Data Bank (PDB ID: 
5C1M) was further optimized for docking by adding hydrogen atoms, removing waters, 
including structure truncation of side chains for Lys-269, Glu-270, and Arg-273, generating the 
physiologically appropriate protonation state and hydrogen-bond assignments.  Receptor 
optimization utilized hydrogen-only restrained minimization was performed using the OPLS3 
force field (Schrödinger, 2016).  Additionally, we defined the putative active-site by 
incorporating key amino residues previously identified through corroborating point-mutation 
studies [Gln-115, Tyr-119, Tyr-139, Tyr-312, Tyr-313, Ile-316 and Tyr-320] (Kane et al., 2006; 
Van et al., 2013; Yan et al., 2005).    
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Figure 30. Sequence alignment of KOR with the MOR template. Identical residues 
are in red, while similar residues are in blue. Helical regions are labeled and 
indicated using yellow background. 
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Figure 31. Ramachandran plot of the best KOR protein model 
showing the dihedral angles of the amino acids. 
 
 
 
 
Opioid Receptor Docking Studies 
Structures of the salvinorin analogues were sketched in Maestro and energy-minimized 
using the LigPrep module implemented in the Schrödinger software package using the OPLS3 
force field (Schrödinger, 2016).  A docking receptor grid for the KOR homology model was 
generated using the centroid of the key residues identified through previous point-mutation 
studies lining the putative binding site: Gln-115, Tyr-119, Tyr-139, Tyr-312, Tyr-313, Ile-316 
and Tyr-320 (Kane et al., 2008; Kane et al, 2006; Yan et al, 2005).  Extra-precision docking 
without constraints was performed utilizing the Glide module of the Schrödinger software 
(Schrödinger, 2016). 
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ADME/T Calculations  
Considering physiochemical properties such as absorption, distribution, metabolism, 
excretion, and toxicity (ADME/T) at the early stage of the drug development process is 
important to avoid downstream drug development issues.  Advances in the computational field 
have steadily improved predictive methods for calculating ADME/T properties (Tao et al., 2015; 
Wang et al. 2015).  As such, pharmaceutically important ADME/T properties of the analogue 
series were selected (Table 7) for calculated evaluation using the Schrödinger QikProp module 
implemented in the Maestro software, using LigPrep OPLS3 force field energy-minimized 
structures for each analogue (Schrödinger, 2016).  
 
Statistical Analyses 
The data was analyzed by a two-way analysis of variance (ANOVA) followed by 
Dunnett’s post hoc test or Bonferroni’s post hoc test.  In vitro data is expressed as Ki or EC50 ± 
SEM  and in vivo data is expressed as mean ± SEM, with differences being considered 
statistically significant when P-values were less than 0.05. Statistical analysis was performed 
with GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA, USA). 
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Table 7.  Schrödinger QikProp Module  ADME/T Descriptors 
 
Properties Description 
Recommended  
Range 
Molecular weight 
(Da) 
Molecular weight of the molecule 130.0 – 725.0 
PSA (Å
2
) 
Van der Waals surface area of polar 
nitrogen and oxygen atoms 
7.0 – 200.0 
Number of 
rotatable bonds 
Number of non-trivial (not CX3), non-
hindered (not alkene, amide, small ring) 
rotatable bonds 
0.0 – 15.0 
QPlogPoct 
(octanol/water) 
Predicted octanol/water partition 
coefficient 
-2.0 – 6.5 
QPlogS  
(aqueous 
solubility) 
Predicted aqueous solubility, log S in 
mol/dm 
-6.5 – 0.5 
QPPCaco (nm/s) 
Predicted Caco-2 cell permeability in 
nm/sec 
[representative for GI-blood barrier] 
<25 is poor 
>500 is great 
QPPMDCK 
(nm/s)
Γ
 
Predicted MDCK cell permeability in 
nm/sec 
[representative for blood-brain barrier] 
<25 is poor 
>500 is great 
Lipinski Rule-of-
5 violations 
Number of violations of Lipinski’s rule of 
five 
 Max. 4 
QPlogHERG 
Predicted IC50 value for blockage of 
HERG K+ channels 
Above -5.0 
QPlogKhsa 
Prediction of binding to human serum 
albu 
-1.5 – 1.5 
% Human Oral 
Absorption 
Predicted human oral absorption on 0 to 
100% scale 
>80 is high 
<25 is poor 
CNS 
Predicted central nervous system activity 
on a –2 (inactive) to +2 (active) scale. 
-2.0  – +2.0 
Data adapted from:  Schrödinger, 2016. 
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CHAPTER 6:  Results and Discussion 
Chemistry 
 
Utilizing the general synthesis procedure (outlined in Chapter 5:  Experimental Methods) 
with the appropriate benzofuran-2-carboxylic acid compound 2-O-salvinorin B benzofuran-2-
carboxylate (P-3l; Figure 32) was synthesized and yielded an amorphous white solid; 
1
H NMR 
(400 MHz, Chloroform-d) δ 7.73 – 7.56 (m, 4H), 7.56 – 7.26 (m, 7H), 6.38 (d, J = 1.9 Hz, 1H), 
5.48 (ddd, J = 32.9, 11.5, 6.7 Hz, 3H), 3.82 – 3.66 (m, 5H), 2.99 – 2.76 (m, 2H), 2.62 – 2.42 (m, 
5H), 2.30 (s, 2H), 2.23 – 2.02 (m, 4H), 1.83 (dd, J = 11.1, 4.3 Hz, 2H), 1.74 – 1.55 (m, 5H), 1.46 
(s, 5H), 1.21 (d, J = 32.8 Hz, 5H).  
13
C NMR (101 MHz, CDCl3) δ 201.34, 171.47, 171.13, 
158.41, 156.00, 144.41, 143.70, 139.44, 128.04, 126.83, 125.23, 123.96, 123.00, 115.14, 112.43, 
108.41, 75.77, 72.05, 64.02, 53.55, 52.01, 51.33, 43.26, 42.22, 38.19, 35.49, 30.85, 18.17, 16.50, 
 
 
Figure 32.  Structure of 2-O-salvinorin B benzofuran-2-
carboxylate (P-3l). 
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15.20.  HRMS (m/z):  [M+Cl] calculated:  569.159, observed:  569.233.  Molecular formula:  
C30H30O9.  Molecular weight:  534.19.  
 
 
Compound 2-O-salvinorin B 1H-indole-2-carboxylate (AK-1401; Figure 33) was 
synthesized utilizing the general synthesis procedure with indole-2-carboxylic acid and yielded 
an amorphous white solid; 
1
H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 1H), 7.71 (d, J = 8.1 
Hz, 1H), 7.51 – 7.31 (m, 5H), 7.17 (t, J = 7.6 Hz, 1H), 6.40 (s, 1H), 5.54 (dd, J = 11.8, 4.9 Hz, 
1H), 5.42 (t, J = 10.0 Hz, 1H), 3.76 (s, 3H), 2.89 – 2.79 (m, 1H), 2.53 (dt, J = 28.9, 8.6 Hz, 3H), 
2.28 – 2.15 (m, 2H), 2.11 (d, J = 10.6 Hz, 1H), 1.86 (d, J = 11.6 Hz, 1H), 1.68 – 1.57 (m, 3H), 
1.48 (s, 2H), 1.20 (s, 2H).  
13
C NMR (101 MHz, CDCl3) δ 201.73, 171.51, 171.08, 160.57, 
143.72, 139.43, 137.12, 127.43, 125.97, 125.90, 125.23, 122.79, 121.03, 111.88, 110.23, 108.39, 
75.36, 72.05, 64.20, 53.64, 52.04, 51.43, 43.46, 42.22, 38.22, 35.52, 30.99, 18.17, 16.51, 15.22.  
HRMS (m/z):  [M-H] calculated:  532.572, observed:  532.174.  Molecular formula:  C30H31NO8.  
Molecular weight:  533.58.   
 
 
Figure 33.  Structure of 2-O-salvinorin B 1H-
indole-2-carboxylate (AK-1401). 
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Compound 2-O-salvinorin B benzo[b]thiophene-2-carboxylate (AK-1402; Figure 34) was 
synthesized utilizing the general synthesis procedure with benzo[b]thiophene -2-carboxylic acid 
and yielded an amorphous white solid; 
1
H NMR (400 MHz, Chloroform-d) δ 8.16 (s, 1H), 7.93 – 
7.85 (m, 2H), 7.53 – 7.38 (m, 4H), 6.40 (dd, J = 1.8, 0.9 Hz, 1H), 5.53 (dd, J = 11.7, 5.2 Hz, 1H), 
5.40 (dd, J = 11.1, 8.8 Hz, 1H), 3.76 (s, 3H), 2.91 – 2.78 (m, 1H), 2.61 – 2.45 (m, 4H), 2.30 – 
2.07 (m, 4H), 1.89 – 1.78 (m, 2H), 1.76 – 1.56 (m, 5H), 1.41 – 1.24 (m, 2H), 1.19 (s, 4H).  13C 
NMR (101 MHz, CDCl3) δ 201.44, 171.52, 171.12, 161.72, 143.72, 142.53, 139.47, 138.63, 
131.53, 127.27, 125.72, 125.21, 125.05, 122.78, 108.42, 75.87, 72.05, 64.12, 53.61, 52.03, 51.41, 
43.39, 42.21, 38.22, 35.51, 30.90, 28.15, 18.17, 16.51, 15.22.  HRMS (m/z):  [M+Cl] calculated:  
585.589, observed:  585.205.  Molecular formula:  C30H30O8S.  Molecular weight:  550.62.   
 
 
 
 
 
 
 
Figure 34.  Structure of 2-O-salvinorin B 
benzo[b]thiophene-2-carboxylate (AK-1402). 
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Compound 2-O-salvinorin B benzofuran-3-carboxylate (AK-1403; Figure 35) was 
synthesized utilizing the general synthesis procedure with benzofuran-3-carboxylic acid and 
yielded an amorphous white solid; 
1
H NMR (400 MHz, Chloroform-d) δ 8.34 (s, 1H), 8.09 – 
7.99 (m, 1H), 7.58 – 7.49 (m, 1H), 7.44 – 7.27 (m, 4H), 6.41 – 6.36 (m, 1H), 5.55 – 5.37 (m, 
2H), 3.73 (s, 3H), 2.89 – 2.77 (m, 1H), 2.57 – 2.39 (m, 3H), 2.28 (s, 1H), 2.21 – 2.04 (m, 3H), 
1.84 – 1.73 (m, 1H), 1.72 – 1.53 (m, 4H), 1.21 (d, J = 36.4 Hz, 5H).  13C NMR (101 MHz, 
CDCl3) δ 201.86, 171.61, 171.18, 162.09, 155.61, 151.75, 143.68, 139.51, 125.51, 125.25, 
124.36, 122.02, 113.63, 111.76, 108.47, 75.08, 72.02, 63.95, 53.50, 51.99, 51.29, 43.28, 42.16, 
38.14, 35.46, 30.98, 29.67, 18.16, 16.49, 15.20.  HRMS (m/z):  [M+Cl] calculated:  569.5294, 
observed:  569.7652.  Molecular formula:  C30H30O9.  Molecular weight:  534.56.   
 
 
 
 
Figure 35.  Structure of 2-O-salvinorin B benzofuran-
3-carboxylate (AK-1403). 
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Compound 2-O-salvinorin B benzo[b]thiophene-3-carboxylate (AK-1405; Figure 36) was 
synthesized utilizing the general synthesis procedure with benzo[b]thiophene -2-carboxylic acid 
and yielded an amorphous white solid; 
1
H NMR (400 MHz, Chloroform-d) δ 8.58 – 8.48 (m, 
2H), 7.92 – 7.85 (m, 1H), 7.59 – 7.37 (m, 5H), 6.40 (dd, J = 1.9, 0.9 Hz, 1H), 5.57 – 5.40 (m, 
3H), 3.75 (s, 4H), 2.85 (dd, J = 9.2, 7.6 Hz, 2H), 2.60 – 2.44 (m, 5H), 2.28 (s, 1H), 2.24 – 2.06 
(m, 3H), 1.90 – 1.77 (m, 2H), 1.75 – 1.58 (m, 5H), 1.47 (s, 4H), 1.19 (s, 4H).  13C NMR (101 
MHz, CDCl3) δ 201.96, 171.62, 171.14, 161.37, 143.70, 140.02, 139.48, 137.87, 136.55, 125.98, 
125.57, 125.25, 125.18, 124.63, 122.56, 108.45, 75.14, 72.05, 64.10, 53.63, 52.01, 51.39, 43.39, 
42.21, 38.20, 35.50, 31.05, 18.18, 16.52, 15.23.  HRMS (m/z):  [M+Cl] calculated:  585.1394, 
observed:  585.5306.  Molecular formula:  C30H30O8S.  Molecular weight:  550.17.   
 
 
 
 
 
Figure 36.  Structure of 2-O-salvinorin B 
benzo[b]thiophene-3-carboxylate (AK-1405). 
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Compound 2-O-salvinorin B 1H-indene-2-carboxylate (AK-1406; Figure 37) was 
synthesized utilizing the general synthesis procedure with 1H-indene-2-carboxylic acid and 
yielded an amorphous white solid;; 
1
H NMR (400 MHz, Chloroform-d) δ 7.89 – 7.83 (m, 1H), 
7.58 – 7.49 (m, 2H), 7.45 – 7.31 (m, 4H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 5.53 (dd, J = 11.6, 5.1 
Hz, 1H), 5.33 (t, J = 10.0 Hz, 1H), 3.75 (d, J = 5.2 Hz, 5H), 2.87 – 2.77 (m, 1H), 2.56 (dd, J = 
13.5, 5.2 Hz, 1H), 2.49 – 2.39 (m, 2H), 2.28 – 2.06 (m, 3H), 1.88 – 1.79 (m, 1H), 1.76 – 1.55 (m, 
4H), 1.48 (s, 3H), 1.18 (s, 3H).  
13
C NMR (101 MHz, CDCl3) δ 202.13, 171.62, 171.14, 163.67, 
144.96, 143.71, 142.79, 142.49, 139.45, 135.73, 127.94, 126.98, 125.23, 124.30, 123.63, 108.41, 
74.98, 72.06, 64.13, 53.67, 51.99, 51.44, 43.43, 42.19, 38.30, 38.23, 35.50, 31.01, 18.18, 16.48, 
15.23.  HRMS (m/z):  [M+Cl] calculated:  567.1794, observed:  567.4084.  Molecular formula:  
C31H32O8.  Molecular weight:  532.21.   
 
 
 
 
 
Figure 37.  Structure of 2-O-salvinorin B 1H-
indene-2-carboxylate (AK-1406). 
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Pharmacological Results 
 
In Vitro Results 
 Briefly, the generated C(22)-fused-heteroaromatic salvinorin A analogues were 
pharmacologically characterized utilizing the following  in vitro scheme:  analysis in a primary 
competitive radioligand binding affinity assay at DOR/KOR/MOR,  analogues that met the 70%-
threshold inhibition proceeded to the secondary competitive radioligand binding affinity assay to 
establish Ki values, with analogues exhibiting  Ki ≤300 nM proceeding to the [
35S]GTP[γS] 
binding assay as a measure of functional activity to established EC50 at the respective receptor. 
 In summarizing the in vitro data (Table 8), it was observed that benzo[b]thiophene-2 and 
benzo[b]thiophene-3, AK-1402 and AK-1405, respectively, failed to meet the 70%-threshold 
inhibition in the primary competitive radioligand binding affinity assay at any of the opioid 
receptors.  This is of interest as they represent the fused-heteroaromatic analogues to the 
previous high-binding affinity heteroaromatic thiphene-2 and thiophene-3 analogues (Table 3).   
 The next comparable analogue is P-3l, the benzofuran-2 analogue which in our assays 
displayed increased binding affinity at DOR and KOR (5-fold and 10-fold, respectively), as well 
as, increased functional activity at both KOR and MOR (14-fold and 8-fold, respectively) — 
when compared to previous reported values (Table 5).  However, this variation may be 
accounted for by the use of different cell-lines used to express the respective sourced human 
opioid receptor cDNA, as those used by the Tidgewell group report DOR activity for their 
salvinorin A control which was not observed in ours (Leon et al.,2013; Tidgewell et al., 2008). 
 Shifting the ester-type link from the substituent 2-position to the substituent 3-position in 
AK-1403, our benzofuran-3 analogue, resulted in abolished DOR/KOR binding affinity and 
strict MOR binding affinity (Ki of 149 nM).  However, the functional activity was reduced when 
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compared to P-3l (MOR EC50 of 210 nM reduced to 950 nM) — however, the assessed 
functional activities of both benzofuran-analogues, P-3l and AK-1403, were higher than that 
previously reported by Tidgewell for P-3l (MOR EC50 of 1,680 nM)(Tidgewell et al., 2008). 
 Incorporation of the indene-2 substituent, AK-1406,  resulted in binding affinity at all 
assessed receptors (Table 8), however only DOR and MOR met the secondary binding affinity 
threshold of Ki ≤300 nM — with a clear preference for MOR (DOR Ki of 279 and MOR Ki of 8).  
Assessment of functional activity by [
35S]GTP[γS] binding further corroborated this MOR 
preference with a MOR EC50 of 85 nM and a DOR EC50 of 894 nM. 
 Of interest was the indole-2 substituent, AK-1401, as this analogue incorporates a 
nitrogen into salvinorin A —  a pharmacophore noted as being unique for  being non-
nitrogenous.  This promoted a MOR/KOR dual-binding affinity, with a 100-fold preference for 
MOR and functional assessment revealed a MOR EC50 of 187 nM. 
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Table 8. In vitro data summary of  C(22)-fused-heteroaromatic salvinorin A analogues. 
Compound Binding Affinity 
Functional Activity 
[
35S]GTP[γS] binding, 
EC50 ± SEM, nM 
 
Delta 
pKi 
±SEM 
Delta 
Ki 
(nM) ± 
SEM 
Kappa 
pKi   
±SEM 
Kappa 
Ki 
(nM) 
±SEM 
Mu 
pKi 
±SEM 
Mu 
Ki 
(nM) 
±SEM 
DOR KOR MOR 
DPDPE 
7.742 
0.0707 
18.12     
1.71 
— — — — 
2.526           
0.427 
— — 
U-69,593 — — 
8.964 
0.0905 
1.087    
0.132 
— — — 
25.62          
4.12 
— 
DAMGO — — — — 
8.748 
0.0995 
1.787      
0.0239 
— — 
7.204             
1.21 
Salvinorin 
A 
— — 
9.021    
0.1034 
0.9534  
0.133 
— — — — — 
P-3l 
7.007 
0.2051 
98.36           
28.1 
8.140      
0.0663    
7.242                        
0.642 
7.670
0.0993 
21.36         
2.85 
367.0           
66.9 
80.88              
8.03 
210.7            
36.5 
AK-1401 — — 
5.998 
0.1246 
1005             
169 
7.979     
0.1262 
10.49              
1.79 
— — 
187.5                   
51.7 
AK-1402 — — — — — — — — — 
AK-1403 — — — — 
6.826 
0.070 
149.40 
 14.0 
— — 
950.7                   
458.4 
AK-1405 — — — — — — — — — 
AK-1406 
6.553 
0.137 
279.9  
51.9 
6.266 
0.086 
541.9  
62.8 
8.068 
0.063 
8.553  
0.715 
894.6                   
50.4 
— 
85.0                   
7.15 
— indicates that 70% inhibition in primary binding affinity 
assay was not achieved 
— indicates that  Ki 
≤300 nM in 
secondary binding 
affinity was not 
achieved 
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In Vivo Results 
I. Antinociceptive Related Assays 
 Based on the preceding in vitro results analogues three of the substituent 2-position 
analogues were selected for in vivo characterization focused towards potential antinociceptive 
effects:  P-3l, AK-1401, and AK-1402.   
 
Acetic Acid-induced Abdominal Writhing Assay 
 As outlined in the experimental section (Chapter 5) the the first chemo-nociceptive mode 
we employed was an acetic acid-induced abdominal writhing assay.  The mice (n = 10) were 
treated with vehicle (10ml/kg, P.O.) as a negative control, indomethacin (20 mg/kg, P.O.) or 
morphine (10 mg/kg, P.O.) as positive controls.  The three selected fused-heteroaromatic 
salvinorin A analogues were administered at three test doses: 1, 3, 10 mg/kg (P.O.).  These 
treatments were 60 minutes prior to the administration of acetic acid solution (IP) and subsequent 
30 minute test period in which writhing movements were measured.  All three of the assessed 
analogues produced statistically significant reduction in writhing movements with P-3l (Figures 
38) active at 3 and 10 mg/kg, and AK-1401(Figures 39) and AK-1402 (Figures 40) producing 
statistically significant reductions at all three tested doses.  These writhing reductions are 
interpreted as a measure of antinociciptive effects in this model. 
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Figure 38.  Acetic acid-induced abdominal writhing assay results:  P-3l.   
 
Effect of P-3l (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced writhes 
in mice. Indomethacin (20 mg/kg, P.O.) and morphine (10 mg/kg, P.O.) were 
used as positive control. Vertical bars represent mean ± SEM of cumulated 
writhing (%) in 30 min for each experimental group. * P ≤ 0.05 using ANOVA 
followed by Dunnet test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Acetic acid-induced abdominal writhing assay results:  AK-1401. 
 
Effect of AK-1401 (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced 
writhes in mice. Indomethacin (20 mg/kg, P.O.) and morphine (10 mg/kg, P.O.) 
were used as positive control. Vertical bars represent mean ± SEM of cumulated 
writhing (%) in 30 min for each experimental group. * P ≤ 0.05 using ANOVA 
followed by Dunnet test. 
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Formalin Assay 
The second chemo-nociceptive model we employed was a formalin assay which allows us to 
examine both direct neurogenic pain and subsequent inflammatory pain.  As outlined in the 
experimental section (Chapter 5) the mice (n = 7) were administered vehicle (10ml/kg, P.O.) as a 
negative control in both phases, morphine (10 mg/kg, SC) as a positive control in first and 
second phases, or indomethacin (20 mg/kg, P.O.) as a positive control in the second phase. The 
three selected fused-heteroaromatic salvinorin A analogues were administered at three test doses: 
1, 3, 10 mg/kg (P.O.).  All treatments, except for morphine were administered 60 minutes prior 
to test, with morphine being administered 30 minutes prior.  Once administered the formalin 
phlogistic agent mice were observed for two periods:  0 to 5 minutes — the first phase (direct 
Figure 40.  Acetic acid-induced abdominal writhing assay results:  AK-1402. 
 
Effect of AK-1402 (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced 
writhes in mice. Indomethacin (20 mg/kg, P.O.) and morphine (10 mg/kg, P.O.) 
were used as positive control. Vertical bars represent mean ± SEM of 
cumulated writhing (%) in 30 min for each experimental group. *P ≤ 0.05 using 
ANOVA followed by Dunnet test. 
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neurogenic pain) and from 15 to 30 minutes — the second phase (inflammatory pain).  Both P-3l 
(Figure 41) and AK-1401 (Figure 42) produced statistically significant reduction in paw licking 
behavior at all three doses, in both neurogenic and inflammatory (1
st
 and 2
nd
) phases.  
Interestingly, in this model, AK-1402 (Figure 43), failed to promote a reduction of paw licking 
behavior during the secondary (inflammatory) phase and was only active in the neurogenic phase 
at the higher doses of 3 and 10 mg/kg. 
 
 
 
 
 
 
Figure 41.  Formalin assay results:  P-31. 
 
Effect of P-3l (1, 3, 10 mg/kg, P.O.), indomethacin (20 mg/kg, P.O.) and morphine (10 
µmoL/kg  P.O.) on the licking time of formalin test, in mice, during the first (0-5 min) 
and second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction 
time, in seconds. * P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05 
(compared with 2
nd
 phase control group) using ANOVA followed by Dunnet test. 
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Figure 42.  Formalin assay results:  AK-1401. 
 
Effect of AK-1401 (1, 3, 10 mg/kg, P.O.), indomethacin (20 mg/kg, P.O.) and morphine 
(10 µmoL/kg  P.O.) on the licking time of formalin test, in mice, during the first (0-5 
min) and second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction 
time, in seconds. * P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05 
(compared with 2
nd
 phase control group) using ANOVA followed by Dunnet test. 
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Figure 43.  Formalin assay results:  AK-1402. 
 
Effect of AK-1402 (1, 3, 10 mg/kg P.O.), indomethacin (20 mg/kg P.O.) and morphine (10 
µmoL/kg  P.O.) on the licking time of formalin test, in mice, during the first (0-5 min) and 
second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction time, in 
seconds. * P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05 (compared with 
2
nd
 phase control group) using ANOVA followed by Dunnet test. 
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Opioid Antagonism Assay 
 To evaluate the preceding formalin assay first phase results for opioid pathway 
involvement we utilized naloxone antagonist model (as outline in the Experimental Methods, 
Chapter 5).  Briefly, we pretreated mice (n =7 ) with either saline (10 ml/kg, IP) as a negative 
control or naloxone (3 mg/kg; IP) as the opioid antagonist.  After 15 minutes the mice received 
one of four treatments:  vehicle, or one of the three selected fused-heteroaromatic salvinorin A 
analogues (10 mg/kg; P.O.) from the previous assay (P-3l, AK-1401, or AK-1402).  Pretreatment 
with naloxone was found to antagonize the reduction previously observed in licking behavior in 
the first phase of the formalin assay in a statistically significant manner with all three analogues 
(Figures 44, 45, 45), supporting the involvement of the opioid receptors in mediating the 
antinociciptive effect in this model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44.  Opioid antagonism assay results:  P-3l. 
 
Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the P-
31 10 mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in 
mice. Vertical bars represent mean ± SEM of pain reaction time, in seconds. * P ≤ 
0.05 (compared control group) and 
#
 P ≤ 0.05 (compared with respectively treated 
group) using ANOVA followed by Dunnet test. 
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Figure 45.  Opioid antagonism assay results:  1401. 
 
Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the AK-
1401 10 mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in 
mice. Vertical bars represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05 
(compared control group) and 
#
 P ≤ 0.05 (compared with respectively treated group) 
using ANOVA followed by Dunnet test. 
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Figure 46.  Opioid antagonism assay results:  1402. 
 
Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the AK-
1402 3 mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in 
mice. Vertical bars represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05 
(compared control group) and 
#
 P ≤ 0.05 (compared with respectively treated group) 
using ANOVA followed by Dunnet test. 
 
 86 
 
 
Hot Plate Assay 
 
 As our thermo-nociceptive model we utilized a hot plate assay.   In this model, mice (n = 
8) were treated either with vehicle control (10 ml/kg, P.O.), morphine (5 mg/kg, P.O.) as a 
positive control, or one of the three selected fused-heteroaromatic salvinorin A analogues (P-3l, 
AK-1401, AK-1402) assessed at 1, 3, and 10 mg/kg (P.O.).  A 30 minute pretreatment latency 
baseline was established for each test mouse.  After treatment latency response to thermal pain 
was measured every 30 minutes (0-180 minutes).  In this model, both P-3l (Figure 47) and AK-
1401 (Figure 48) produced statistically significant increase in latency response to thermal pain at 
doses 3 and 10 mg/kg for the entire 180 minute test duration.  AK-1402 also produced a 
 
Figure 47.  Hot plate assay results:  P-3l. 
 
Effect of P-31 (1, 3, 10 mg/kg, P.O.) or morphine (10 mg/kg, P.O.- positive control) 
on the hot plate test, in mice (n = 8).  The values were expressed as mean ± SEM of 
the latency to nociceptive behavior, in seconds. *P ≤ 0.05 compared to control group, 
according to two-way ANOVA followed by Bonferroni’s post-hoc test. 
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statistically significant increase in latency response to thermal pain at 3 and 10 mg/kg for 150 
minutes of the test period before returning to baseline by 180 minutes (Figure 49).  Additionally, 
both P-3l and AK-1402 also showed activity at the 1 mg/kg dose from 60 to 150 minutes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48.  Hot plate assay results:  AK-1401. 
 
Effect of AK-1401 (1, 3, 10 mg/kg, P.O.) or morphine (10 mg/kg, P.O., positive 
control) on the hot plate test, in mice (n = 8).  The values were expressed as mean ± 
SEM of the latency to nociceptive behavior, in seconds. *P ≤ 0.05 compared to 
control group, according to two-way ANOVA followed by Bonferroni’s post-hoc 
test. 
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Figure 49.  Hot plate assay results:  AK-1402. 
 
Effect of AK-1402 (1, 3, 10 mg/kg P.O.) or morphine (10 mg/kg, P.O., positive 
control) on the hot plate test, in mice (n = 8).  The values were expressed as mean 
± SEM of the latency to nociceptive behavior, in seconds. *P ≤ 0.05 compared to 
control group, according to two-way ANOVA followed by Bonferroni’s post-hoc 
test. 
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II. Antidepressant Related Assays 
Based upon the initial in vitro results establishing the preference of AK-1401 for MOR 
(100-fold more than KOR) and the MOR functional activity at EC50 of 187 nM, as well as, the in 
vitro antinociceptive activities established in both chemo-nociceptive and thermo-nociceptive 
models this analogue was selected for further characterization for potential antidepressant-like 
activity. 
 
Forced SwimTest 
 Our first model used to assess potential antidepressant-like effects of AK-1401 was the 
forced swim test that measures effect on swimming time and immobility.  Test mice (n = 10) 
were treated with either a vehicle control (10 ml/kg, P.O.), imipramine (IMI, 15 mg/kg, P.O.) or 
 
Figure 50.  Forced swim test, swimming time results:  AK-1401. 
 
The effect of oral administration of vehicle, AK-1401 at 1, 3, 10 mg/kg, positive control 
imipramine (IMI) at 15 mg/kg, and vehicle on the swimming time (B) and immobility 
time (C) in the forced swimming test. Each column represents the mean ± S.E.M. of 10 
animals. *P < 0.05, *P < 0.01 or *P < 0.001 versus vehicle treated group (one way 
ANOVA followed by Dunnett´s test). 
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AK-1401 at 1, 3, or 10 mg/kg (P.O.) and assessed one hour after for activity.  AK-1401 was 
found to produce statistically significant increases in swimming time (Figure 50) and reduced 
immobility time (Figure 51) at doses 3 and 10 mg/kg.  These effects are interpreted as 
antidepressant-like activity in this model. 
 
 
 
 
 
 
 
 
 
 
Figure 51.  Forced swim test, immobility time results:  AK-1401. 
 
The effect of oral administration of vehicle, AK-1401 at 1, 3, 10 mg/kg, positive control 
imipramine (IMI) at 15 mg/kg, and vehicle on the swimming time (B) and immobility 
time (C) in the forced swimming test. Each column represents the mean ± S.E.M. of 10 
animals. *P < 0.05, *P < 0.01 or *P < 0.001 versus vehicle treated group (one way 
ANOVA followed by Dunnett´s test). 
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Tail Suspension Test  
 Our second model used to assess potential antidepressant-like effects of AK-1401 was a 
modified version of tail suspension test (TST) that measures immobility.  Test mice (n = 10) 
were treated with either a vehicle control (10 ml/kg, P.O.), imipramine (IMI, 15 mg/kg, P.O.) or 
AK-1401 at 1, 3, or 10 mg/kg (P.O.) and assessed one hour after for activity.  Once more, AK-
1401 was found to produce statistically significant activity (i.e. reduction in immobility) at doses 
3 and 10 mg/kg (Figure 52) — these results further indicate antidepressant-like activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52.  Tail suspension test results:  AK-1401. 
 
The effect of oral administration of AK-1401 at the doses of 1, 3, 10 mg/kg and 
positive control imipramine (IMI) 15 mg/kg or vehicle on immobility time in the 
tail suspension test (one-way ANOVA followed by Dunnett’s test). 
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III. Anxiolytic Related Assay  
Open Field Test 
Lastly, we utilized a circular open field test (OFT) to assess the potential anxiolytic-like 
effects of AK-1401 on exploratory activity with the endpoints being:  freezing time, total 
sectorial crossing, rearing number, and center crossing.  Test mice (n = 10) were treated with 
either vehicle (10 ml/kg, P.O.), diazepam (DZP, 5 mg/kg, P.O.), or AK-1401 at 1, 3, or 10 mg/kg 
(P.O.).  However, AK-1401 was largely ineffective at altering these behaviors (Figures 53 and 
54), except for center crossing (Figure 54-D) where it significantly increased this exploratory 
behavior.  While these results largely indicate that AK-1401 does not promote anxiolytic-like 
effects in mice, the effect on exploratory behavior may suggest  that further anxiolyitc 
characterization would be advisable. 
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 Figure 53.  Open field test results, Freezing time and Total crossing:  AK-1401. 
The effect of acute oral administration of AK-1401 at 1, 3, 10 mg/kg, positive control 
diazepam (DZP) 5 mg/kg, or vehicle in the open field exploratory assay on freezing 
time (A), the total crossing (B), number of rearing events. Each column represents the 
mean ± S.E.M. of 10 animals. *P < 0.05 and ***P<0.001 versus vehicle treated group 
(one way ANOVA followed by Dunnett´s test). 
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Figure 54.  Open field test results, Number of rearing and crossing at the center:  
AK-1401. 
 
The effect of acute oral administration of AK-1401 at 1, 3, 10 mg/kg, positive 
control diazepam (DZP) 5 mg/kg, or vehicle in the open field exploratory assay on 
freezing time (C) and crossing at the center of the open-field (D). Each column 
represents the mean ± S.E.M. of 10 animals. *P < 0.05 and ***P<0.001 versus 
vehicle treated group (one way ANOVA followed by Dunnett´s test). 
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Computational Modeling 
Opioid Receptor Docking Studies  
KOR Docking Studies 
  The Schrödinger Prime protein-structure prediction program was utilized to calculate 
the molecular mechanics with generalized born surface area (MM-GBSA) of both salvinorin A 
and AK-1401 complexed with KOR (Schrödinger, 2017; Vilar et al., 2010).  As expected from 
in vitro binding affinity studies (Table 8; in vitro established salvinorin A KOR Ki of 0.9 nM and 
AK-1401 KOR Ki of 1,005 nM), our docking calculations indicated a lower binding free energy 
for the KOR/salvinorin A complex (Binding Energy = −61.674 kcal/mol) than for the KOR/AK-
1401 complex (Binding Energy = −53.046 kcal/mol).  Additionally, this optimized KOR model 
showed that AK-1401 possessed a binding orientation analogous to salvinorin A except at the 
C(22)-position indole moiety (Figure 55).  This predicted orientation of the AK-1401 indole 
moiety differed from the acetoxy moiety of salvinorin A due to increased solvent exposure, lack 
of significant hydrophobic and polar interactions — which may account for the lower 
experimentally derived KOR binding affinity of AK-1401compared to salvinorin A (Table 8).   
The predicted binding pose indicated the fused-tricyclic core of salvinorin A is vertically 
oriented towards TM2, TM3, and TM6 and surrounded, primarily, by the side chains of residues: 
Gln-115, Ile-135, Asp-138, Tyr-139, Met-142, Val-230, Ile-294, and Ile-316 (Figure 56).  
Salvinorin A exhibited strong hydrophobic interactions with Tyr-139, Met-142, Ile-294, and Ile-
316.  The ketone moiety at the C(1)-position hydrogen-bonded with Gln-115.  The C(12)-
position furan moiety interacted in a deeper sub-pocket characterized by key interactions with 
Tyr-320 and Trp-287 through aromatic π-π stacking and exhibited hydrophobic interactions with 
residues:  Val-108, Met-142, Ile-290, and Ile-316.  The C(2)-position acetoxy-group was shown 
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Figure 55.  Overlay of AK-1401 (cyan carbons) and salvinorin A (yellow carbons).  
 
to hydrogen-bond with Gln-115 and was delineated by residues:  Ile-135, Asp-138, and Cys-210.  
The C(4)-position carbomethoxy was situated in a small pocket bound by residues: Lys-227, 
Glu-297, Leu-212 and Tyr-312 (Figure 57).  Interestingly, this optimized docking pose was 
found to correspond well with a previously reported site-directed mutagenesis derived docking 
pose of salvinorin A (Kane et al., 2006).  The primary difference observed between these two 
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proposed docking poses is that at the C(2)-position the Kane group reported a Tyr-313 
hydrophobic interaction while in our model the interaction is calculated to be with Gln-115 
(Figure 57). 
 
 
 
 
 
 
 
 
 
Figure 56.  Predicted binding oreintation of salvinorin A (yellow carbons) 
into the active-state KOR model (key active site residues shown with grey 
carbons). 
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Figure 57.  Predicted key-residue interactions of KOR/salvinroin A complex.
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MOR Docking Studies 
Similar to the method described for our KOR model a receptor grid was prepared for 
MOR centered on the centroid of the co-crystallized agonist (BU72) of PDB: 5C1M.  The amino 
acid terminus (residues Gly-52-Met-65) of the active state MOR forms a lid over the putative 
orthosteric site.  Therefore we utilized the Induced Fit docking protocol within the Schrödinger 
software suite to examine the potential MOR/AK-1401orientation and interactions, chosen due to 
the activity established in the previous in vitro and in vivo assays.  This model was optimized 
utilizing the OPLS3 force field optimization and extra-precision docking mode of the Glide 
module in the Schrödinger software suite, without the inclusion of specified docking constraints 
— to allow for a comprehensive docking range to be examined. 
The docking results, and MM-GBSA calculations for each, provided a range of putative 
binding poses for AK-1401 within the active state MOR model.  The best pose based on 
calculated Glide Gscore value (Glide Gscore = −9.887) and binding energy value (Binding 
Energy = −96.604 kcal/mol) revealed that  AK-1401  exhibited strong hydrogen-bonding 
between Gln-124 and the amine on the C(22)-indole, as well as at the ketone moiety of the C(2)-
position (Figure 58).  In this pose, the C(22)-indole moiety was bounded by key residues (Tyr-
128, Trp-318, Phe-320 and Ile-322) forming a hydrophobic-pocket.  In addition, the C(22)-indole 
moiety also participated in aromatic π-π stacking with His-319 and Trp-318.  The C(12)-position 
furanyl moiety showed hydrogen-bonding with Gly-52 and aromatic π-π stacking with Phe-221.  
The C(4)-position carbomethoxy was oriented towards a sub-pocket delineated by residues:  
Asp-147, Tyr-148 and Met-151.  Interestingly, this pose of AK-1401 (Figure 59) did not show 
direct interactions, such as hydrogen-bonding, with Asp-147 — an interaction which is largely 
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conserved for MOR classical opioid ligands but not observed with salvinorin A (Manglik et al., 
2012; Yuan et al., 2015; Yuan et al., 2013). 
  
 
 
 
 
 
Figure 58.  Predicted key-residue interactions of MOR/AK-1401 complex. 
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Figure 59.   The putative binding mode of AK-1401 (yellow carbons) into the 
active-state MOR model (key active site residues shown with grey carbons). 
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ADME/T Calculations 
Lastly, due to the high degree of homology with this bioisosteric C(22)-fused-
heteroaromatic salvinorin A analogue series the Schrödinger QikProp module calculated 
ADME/T properties were similarly homologous (Table 9) and, largely, indicated reasonable 
drug-like properties for this series (with Schrödinger QikProp recommend range values derived 
from a dataset comprised of 95% of currently marketed drugs; Schrödinger, 2016).  The 
predicted logP and logS values were in the recommended range to indicate this series would 
likely possess good aqueous solubility and low lipophilicity.  Additionally, except for a single 
violation (due to high molecular weights) this series also follows Lipinski’s Rule of Five, 
supporting ease of solubility and oral availability of these compounds.  This was further 
supported by high Percent Human Oral Absorption values (all above 80% which predicts good 
oral availability) — maintained by our in vivo models by effective use of P.O. administration 
route.  The only calculated property of concern was the QPlogHERG values, which were outside 
the recommend range — indicating potential hERG potassium channel interaction and possible 
drug-induced cardiac effects (i.e. cardiac arrhythmia) (Sanguinetti and Tristani-Firouzi, 2006).   
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Table 9.  Schrödinger QikProp Module ADME/T Calculations. 
Properties P-3l 
AK-
1401 
AK-
1402 
AK-
1403 
AK-
1404 
AK-
1405 
AK-
1406 
AK-
1407 
Molecular 
weight (Da) 
534.56 533.57 550.62 534.56 533.57 550.62 532.58 532.58 
PSA (Å
2
)
†
 139.16 142.93 129.44 137.60 142.63 127.73 129.76 127.91 
Number of 
rotatable 
bonds 
3 3 3 3 3 3 3 3 
QPlogPoct 
(octanol/wat
er)
‡
 
3.74 4.14 4.32 3.67 4.37 4.40 4.23 4.18 
QPlogS 
(aqueous 
solubility)
§
 
-5.54 –6.70 -6.19 -5.15 -6.24 -6.15 -6.06 -5.99 
QPPCaco 
(nm/s)
¶
 
435.39 270.09 434.81 498.42 292.29 555.87 498.23 517.88 
QPPMDCK 
(nm/s)
Γ
 
201.38 120.19 321.46 233.07 130.90 500.18 232.97 242.92 
Lipinski 
Rule-of-5 
violations 
1 1 1 1 1 1 1 1 
QPlogHER
G
Δ
 
-6.49 –6.70 -6.41 -6.20 -6.30 -6.31 -6.42 -6.34 
QPlogKhsa

 0.21 0.71 0.43 0.16 0.63 0.42 0.44 0.42 
% Human 
Oral 
Absorption 
83.16 81.74 86.51 83.78 83.71 88.92 87.04 87.09 
CNS -2 -2 -2 -1 -2 -1 -2 -2 
Physicochemical properties calculated using QikProp. Range is for 95% of known 
drugs.  Recommended range, based on that of 95% of marketed drugs: Molecular 
weight (130–725 Da); † Van der Waals surface area of polar nitrogen and oxygen 
atoms (7–200 Å2); ‡ Predicted octanol/water partition coefficient (−2–6.5); § 
Predicted aqueous solubility, log S (−6.5–0.5); ¶ Predicted apparent Caco-2 cell 
permeability (<25 nm/s poor; >500 nm/s great); 
Γ
 Predicted apparent MDCK cell 
permeability (<25 nm/s poor; >500 nm/s great); 
Δ
 Predicted IC50 value for blockage 
of HERG K
+
 channels (it is a serious concern if below −5);  Prediction of binding to 
human serum albumin (−1.5–1.5 acceptable).  CNS range:  -2 (inactive) to +2 
(active).   
 
Schrödinger, 2017. 
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CHAPTER 7:  Conclusions 
 This study further supports the importance of the continued development of new 
salvinorin A analogues as essential research tools to ascertain potential three-dimensional ligand 
binding requirements, functional activities, and pharmacological consequences mediated through 
the clinically important opioid receptors.  This series of pharmacologically evaluated C(22)-
fused-heteroaromatic salvinorin A analogues (i.e. P-3l, AK-1401, AK-1402, AK-1403, AK-
1405, and AK-1406) revealed a range of activities.  Though it would be difficult to conclude a 
definitive structure-activity-relationship, trends are observed in the generated data that allow for 
a number of tentative conclusions:   
 
o This study corroborates the effect that aromaticity has on inducing MOR binding affinity 
in salvinorin A — a lead pharmacophore typified by KOR selectivity. 
With one caveat:   this trend was not observed with either of the 
benzo[b]thiophene-analogues (AK-1402 and AK-1405) as neither produced minimum 
inhibition in the primary competitive radioligand binding assay.  However, subsequent in 
vivo antinociceptive assessment of AK-1402, in both chemo-nociceptive (acetic acid-
induced abdominal writhing assay and formalin assay, first-phase) and thermo-
nociceptive (hot plate assay) models, revealed statistically significant activity mediated 
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through the opioid receptors (determined via the opioid antagonism assay). — indicating 
further assessment would be advisable  
 
o This study further supports the potential for oral administration of aromatic analogues of 
salvinorin A — a lead pharmacophore typified by oral inactivity. 
This route of administration was previously employed for PR-38 in models of 
gastrointestinal hypermotility and antipruritic activity (Table 6) and was the elected route 
of effective administration (i.e. active) in our study for P-3l, AK-1401, and AK-1402 in 
respective antinociceptive and antidepressant-like assays. 
 
o This study further bolsters the development of salvinorin A analogues towards potential 
clinical applications, specifically, antinociception and depression, with increased 
durations of activity when compared to other salvinorin compounds. 
This line of development has a steadily growing body of literature indicating 
potentially useful clinical applications (e.g. antinociceptive, anti-addictive, antipruritic, 
neuroprotective, etc.) of not only the lead, salvinorin A, but an increasing number of 
analogues, such as Herkinorin (avoids β-arrestin-2 recruitment, receptor internalization, 
and tolerance development), PR-38 (orally active, promotes both antinociceptive and 
antipruritic activities) and, in this study, P-3l, AK-1401, and AK-1402 (respectively, 
promoting statistically significant antinociceptive and antidepressant-like effects). 
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o Lastly, the computationally derived ADME/T properties of this study indicated potential 
hERG potassium channel interaction by this series of salvinorin A analogues as all 
predicted values were outside of the recommended safety range. 
While this pharmacological contradiction has not been reported in the salvinorin 
class, due to the potential for drug-induced cardiac effects (i.e. cardiac arrhythmia) 
mediated through hERG potassium channel interaction, assessment would be advisable 
prior to further drug development considerations. 
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Binding Affinity of Salvinorin A 
Compound 
Kappa 
pKi +/- SEM 
Kappa 
Ki (nM) +/- SEM 
Salvinorin 
A 
9.0210.1034 0.95340.133 
Naloxone 
HCl 
8.9640.0905 1.0870.132 
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Binding Affinity of P-3l 
Compound 
Delta 
pKi +/- SEM 
Delta 
Ki (nM) +/- SEM 
P-3l 7.0070.2051 98.3628.1 
Naloxone 
HCl 
7.7420.0707 18.121.71 
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Binding Affinity of P-3l 
Compound 
Kappa 
pKi +/- SEM 
Kappa 
Ki (nM) +/- SEM 
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Binding Affinity of P-3l 
Compound 
Mu 
pKi +/- SEM 
Mu 
Ki (nM) +/- SEM 
P-3l 7.6700.0993 21.362.85 
Naloxone 
HCl 
8.7480.0995 1.787.0239 
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[
35S]GTP[γS] Opioid Functional Assessment for P-3l 
Compound Type 
Delta 
EC50 (nM) 
Type 
Kappa 
EC50 (nM) 
Type 
Mu 
EC50 (nM) 
P-3l 
Full 
Agonist 
367.0  
66.9 
Full 
Agonist 
80.88  
8.03 
Full 
Agonist 
210.7  36.5 
Control DPDPE 
2.526  
0.427 
U69,693 
25.62  
4.12 
DAMGO 7.204  1.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G T P  S  D e lta  A g o n is t F u n c t io n a l A s s a y
L o g  C o n c e n tra t io n  (M )
P
e
r
c
e
n
t 
O
v
e
r
 B
a
s
a
l
-1 2 -1 0 -8 -6 -4 -2
-2 0
0
2 0
4 0
6 0
8 0
C o n tro l
LogEC50
EC50
-6.435
3.670e-007
-8.598
2.526e-009
C o m p o u n d
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G T P  S  K a p p a  A g o n is t  F u n c tio n a l A s s a y
L o g  C o n c e n tra t io n  (M )
P
e
r
c
e
n
t 
O
v
e
r
 B
a
s
a
l
-1 2 -1 0 -8 -6 -4
-5 0
0
5 0
1 0 0
1 5 0
2 0 0
C o n tro l
LogEC50
EC50
-7.092
8.088e-008
-7.591
2.562e-008
C o m p o u n d
G T P  S  M u  A g o n is t  F u n c t io n a l A s s a y
L o g  C o n c e n tra t io n  (M )
P
e
r
c
e
n
t 
O
v
e
r
 B
a
s
a
l
-1 2 -1 0 -8 -6 -4
-4 0
-2 0
0
2 0
4 0
6 0
8 0
C o n tro l
LogEC50
EC50
-6.676
2.107e-007
-8.142
7.204e-009
C o m p o u n d
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Binding Affinity of AK-1401 
Compound 
Kappa 
pKi +/- SEM 
Kappa 
Ki (nM) +/- SEM 
AK-1401 5.9980.1246 1005169 
Naloxone 
HCl 
8.9640.0905 1.0870.132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-1 4 -1 2 -1 0 -8 -6 -4 -2
0
5 0
1 0 0
1 5 0
lo g  [H L -0 1 0 ] M
%
 B
in
d
in
g
A k -1 4 0 1
Ki
Ak-1401
1.005e-006
IC50
Ak-1401
2.010e-006
Control
1.066e-009
Control
2.131e-009
C o n tro l
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Binding Affinity of AK-1401 
Compound 
Mu 
pKi +/- SEM 
Mu 
Ki (nM) +/- SEM 
AK-1401 7.9790.1262 10.491.79 
Naloxone 
HCl 
8.7480.0995 1.787.0239 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-1 4 -1 2 -1 0 -8 -6 -4
0
5 0
1 0 0
1 5 0
Ki
Ak-1401
1.049e-008
IC50
Ak-1401
2.097e-008
lo g  [H L -0 1 0 ] M
%
 B
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d
in
g
A k -1 4 0 1
Control
1.066e-009
Control
2.131e-009
C o n tro l
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[
35S]GTP[γS] Opioid Functional Assessment for AK-1401 
Compound Type 
Delta 
EC50 
(nM) 
Type 
Kappa 
EC50 (nM) 
Type 
Mu 
EC50 
(nM) 
AK-1401 — — — — 
Full 
Agonist 
187.5  51.7 
Control — — — — DAMGO 7.204  1.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G T P  S  M u  A g o n is t  F u n c t io n a l A s s a y
L o g  C o n c e n tra t io n  (M )
P
e
r
c
e
n
t 
O
v
e
r
 B
a
s
a
l
-1 2 -1 0 -8 -6 -4
-2 0
0
2 0
4 0
6 0
8 0
C o n tro l
LogEC50
EC50
-6.727
1.875e-007
-8.378
4.185e-009
C o m p o u n d
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Binding Affinity of AK-1403 
Compound 
Mu 
pKi +/- SEM 
Mu 
Ki (nM) +/- SEM 
AK-1403 6.826 0.070 149.4 14.0 
Naloxone 
HCl 
8.718 0.071 1.914 0.182 
 
 
 
 
 
 
Binding Assay - Mu
-10 -8 -6 -4 -2
-50
0
50
100
150
Naloxone - Mu
Ki
AK-1403
1.494e-007
Naloxone - Mu
1.755e-009
IC50
AK-1403
2.988e-007
Naloxone - Mu
3.511e-009
AK-1403
LOG(M)
%
 o
f 
C
o
n
tr
o
l
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[
35S]GTP[γS] Opioid Functional Assessment for AK-1403 
Compound Type 
Delta 
EC50 (nM) 
Type 
Kappa 
EC50 (nM) 
Type 
Mu 
EC50 (nM) 
AK-1403 — — — — 
Partial 
agonist 
40% 
950.7 458.4 
Control — — — — DAMGO 22.71  2.96 
 
 
 
 
 
 
GTPS Mu Agonist Functional Assay
-12 -10 -8 -6 -4 -2
-50
0
50
100
150
AK-1403
DAMGO
EC50
AK-1403
9.507e-007
DAMGO
3.963e-008
Log(M)
%
 o
v
e
r 
b
a
s
a
l
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Binding Affinity of AK-1406 
Compound 
Delta 
pKi +/- SEM 
Delta 
Ki (nM) +/- SEM 
AK-1406 6.553 0.137 279.9 51.9 
Naloxone 
HCl 
7.522 0.059 30.03 2.36 
 
 
 
 
 
 
 
 
Binding Assay - Delta
-10 -8 -6 -4 -2
-50
0
50
100
150
Naloxone - Delta
Ki
AK-1406
2.799e-007
Naloxone - Delta
3.094e-008
IC50
AK-1406
5.599e-007
Naloxone - Delta
6.188e-008
AK-1406
LOG(M)
%
 o
f 
C
o
n
tr
o
l
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Binding Affinity of AK-1406 
Compound 
Kappa 
pKi +/- SEM 
Kappa 
Ki (nM) +/- SEM 
AK-1406 6.266 0.086 541.9 62.8 
Naloxone 
HCl 
8.648 0.071 2.249 0.212 
 
 
 
 
 
 
 
Binding Assay - Kappa
-12 -10 -8 -6 -4 -2
0
50
100
150
Naloxone - Kappa
Ki
AK-1406
5.419e-007
Naloxone - Kappa
2.572e-009
IC50
AK-1406
1.084e-006
Naloxone - Kappa
5.143e-009
AK-1406
LOG(M)
%
 o
f 
C
o
n
tr
o
l
 163 
 
Binding Affinity of AK-1406 
Compound 
Mu 
pKi +/- SEM 
Mu 
Ki (nM) +/- SEM 
AK-1406 8.068 0.063 8.553 0.715 
Naloxone 
HCl 
8.718 0.071 1.914 0.182 
 
 
 
 
 
 
 
 
Binding Assay - Mu
-10 -8 -6 -4 -2
-50
0
50
100
150
Naloxone - Mu
Ki
AK-1406
8.553e-009
Naloxone - Mu
1.858e-009
IC50
AK-1406
1.711e-008
Naloxone - Mu
3.716e-009
AK-1406
LOG(M)
%
 o
f 
C
o
n
tr
o
l
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[
35S]GTP[γS] Opioid Functional Assessment for AK-1406 
Compound Type 
Delta 
EC50 (nM) 
Type 
Kappa 
EC50 
(nM) 
Type 
Mu 
EC50 
(nM) 
AK-1406 
Full 
agonist 
894.5  
50.4 
— — 
Full 
agonist 
82.0  7.15 
Control DPDPE 
1.121   
0.093 
— — DAMGO 
22.71  
2.96 
 
 
 
 
 
 
GTPS Delta Agonist Functional Assay
-12 -10 -8 -6 -4 -2
-50
0
50
100
150
200
AK-1406
DPDPE
EC50
AK-1406
8.946e-007
DPDPE
1.204e-009
Log(M)
%
 o
v
e
r 
b
a
s
a
l
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GTPS Mu Agonist Functional Assay
-12 -10 -8 -6 -4 -2
-50
0
50
100
150
200
AK-1406
DAMGO
EC50
AK-1406
8.200e-008
DAMGO
2.343e-008
Log(M)
%
 o
v
e
r 
b
a
s
a
l
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Binding Assay Information 
Opioid Binding Assays 
 
DOR KOR MOR 
Assay Buffer:  
50 mM Tris-HCl, pH 7.4 
Buffer 
50 mM Tris-HCl, pH 
7.4 Buffer 
50 mM Tris-HCl, 
pH 7.4 Buffer 
Assay Volume:  0.2 mL 0.2 mL 0.2 mL 
Radioligand: 
Enkephalin(DPDPE), 
[Tyrosyl-3,5-
3
H(N)] 
U-69,593, 
[Phenyl-3,4-
3
H] 
DAMGO,  
[Tyrosyl-3,5-
3
H(N)] 
Radioligand 
Manufacture/Cat#: 
Perkin Elmer, Cat# 
NET922 
Perkin Elmer, Cat# 
NET952 
Perkin Elmer, Cat# 
NET902 
Radioligand 
Concentration (Kd): 
1.615 nM 1.197 nM 2.295 nM 
  
 
  
 
Receptor Membrane: 
HEKhDOR  
P7 1/20/17 
HEKhKOR  
P10  1/26/17 
HEKhMOR  
P15  5/3/16 
 Membrane 
Concentration: 
7 g/well 3 g/well 25 g/well 
  
 
    
Nonspecific Binding 
Control (NSB): 
DPDPE  
(Tocris Bioscience, Cat# 
1431) 
U69,593 
DAMGO  
(Tocris Bioscience, 
Cat# 1171) 
NSB Concentration: 10 M 10 M 10 M 
  
 
    
Assay Incubation: 60 min @ room temperature 
60 min @ room 
temperature 
60 min @ room 
temperature 
Filter Plate: 
UniFilter-96 GF/B,  
pre-treated w/0.3% BSA 
UniFilter-96 GF/B,  
pre-treated w/0.3% 
BSA 
UniFilter-96 GF/B, 
pre-treated w/0.3% 
BSA 
Range of compound 
dilutions: 
100 M nM – 560 pM 100 M nM – 560 pM 
100 M nM – 560 
pM 
Range of control 
dilutions: 
3 M – 17 pM 3 M – 17 pM 3 M – 17 pM 
Fold increment  for 
serial dilution: 
3-fold 3-fold 3-fold 
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APPENDIX E:   
In Vivo Datasets 
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I. Antinociceptive related assays 
Acetic Acid-induced Abdominal Writhing Assay 
0
25
50
75
100
Vehicle 10 mL/kg
P-31 1 mg/kg
P-31 3 mg/kg*
P-31 10 mg/kg
Indomethacin 20 mg/kg
Morphine 10 mg/kg
*
**
N
u
m
b
e
r 
o
f 
w
ri
th
e
s
  
(%
)
 
 
Effect of P-3l (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced writhes in mice. 
Indomethacin (20 mg/kg P.O.) and morphine (10 mg/kg P.O.) were used as positive control. 
Vertical bars represent mean ± SEM of cumulated writhing (%) in 30 min for each experimental 
group. * P ≤ 0.05 using ANOVA followed by Dunnet test. 
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Effect of AK-1401 (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced writhes in mice. 
Indomethacin (20 mg/kg P.O.) and morphine (10 mg/kg P.O.) were used as positive control. 
Vertical bars represent mean ± SEM of cumulated writhing (%) in 30 min for each experimental 
group. * P ≤ 0.05 using ANOVA followed by Dunnet test. 
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0
25
50
75
100
Vehicle 10 mL/kg
AK-1402 1 mg/kg
AK-1402 3 mg/kg
* AK-1402 10 mg/kg
Indomethacin 20 mg/kg
Morphine 10 mg/kg
*
*
**
N
u
m
b
e
r 
o
f 
w
ri
th
e
s
  
(%
)
 
 
Effect of AK-1402 (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced writhes in mice. 
Indomethacin (20 mg/kg P.O.) and morphine (10 mg/kg P.O.) were used as positive control. 
Vertical bars represent mean ± SEM of cumulated writhing (%) in 30 min for each experimental 
group. *P ≤ 0.05 using ANOVA followed by Dunnet test. 
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Formalin Assay 
0
25
50
75
100
125
150
1
st
 phase
2
nd
 phase
10 mL/kg
   Vehicle
1.0 3.0 10.0
p (mg/kg)
 20 mg/kg
Indomethacin
10 mg/kg
 Morphine
p.o.
*
#
#
# #
* *
L
ic
k
in
g
 t
im
e
 (
s
)
*
#
 
 
Effect of P-3l (1, 3, 10 mg/kg, P.O.), indomethacin (20 mg/kg, P.O.) and morphine (10 µmoL/kg  
P.O.) on the licking time of formalin test, in mice, during the first (0-5 min) and second phase 
(15-30 min). Vertical bars represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05 
(compared with 1
st
 phase control group) and 
#
P ≤ 0.05 (compared with 2nd phase control group) 
using ANOVA followed by Dunnet test. 
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0
25
50
75
100
125
150
1
st
 phase
2
nd
 phase
10 mL/kg
   Vehicle
1.0 3.0 10.0
AK140 (mg/kg)
 20 mg/kg
Indomethacin
10 mg/kg
 Morphine
p.o.
*
#
#
# #
* *
*
#
L
ic
k
in
g
 t
im
e
 (
s
)
 
 
Effect of AK-1401 (1, 3, 10 mg/kg, P.O.), indomethacin (20 mg/kg, P.O.) and morphine (10 
µmoL/kg  P.O.) on the licking time of formalin test, in mice, during the first (0-5 min) and 
second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction time, in seconds. 
* P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05 (compared with 2nd phase 
control group) using ANOVA followed by Dunnet test. 
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0
25
50
75
100
125
150
1
st
 phase
2
nd
 phase
10 mL/kg
   Vehicle
1.0 3.0 10.0
AK1402 (mg/kg)
 20 mg/kg
Indomethacin
10 mg/kg
 Morphine
p.o.
# #
*
*
*
#L
ic
k
in
g
 t
im
e
 (
s
)
 
 
Effect of AK-1402 (1, 3, 10 mg/kg P.O.), indomethacin (20 mg/kg P.O.) and morphine (10 
µmoL/kg  P.O.) on the licking time of formalin test, in mice, during the first (0-5 min) and 
second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction time, in seconds. 
* P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05 (compared with 2nd phase 
control group) using ANOVA followed by Dunnet test. 
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Opioid Antagonism Assay 
0
25
50
75
100
Saline 10 mL/kg i.p.
Naloxone 3 mg/kg i.p.
  Vehicle
10 mL/kg
   P-31
10 mg/kg
Morphine
10 mg/kg
p.o.
*
#
*
#
L
ic
k
in
g
 t
im
e
 (
s
)
 
 
Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the P-31 10 
mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in mice. Vertical bars 
represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05 (compared control group) 
and 
#
 P ≤ 0.05 (compared with respectively treated group) using ANOVA followed by Dunnet 
test. 
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0
25
50
75
100
Saline 10 mL/kg i.p.
Naloxone 3 mg/kg i.p.
  Vehicle
10 mL/kg
   AK-1401
10 mg/kg
Morphine
10 mg/kg
p.o.
*
#
*
#
L
ic
k
in
g
 t
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e
 (
s
)
 
 
Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the AK-1401 10 
mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in mice. Vertical bars 
represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05 (compared control group) 
and 
#
 P ≤ 0.05 (compared with respectively treated group) using ANOVA followed by Dunnet 
test. 
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0
25
50
75
100
Saline 10 mL/kg i.p.
Naloxone 3 mg/kg i.p.
  Vehicle
10 mL/kg
   AK-1402
3 mg/kg
Morphine
10 mg/kg
p.o.
*
#
*
#
L
ic
k
in
g
 t
im
e
 (
s
)
 
 
Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the AK-1402 3 
mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in mice. Vertical bars 
represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05 (compared control group) 
and 
#
 P ≤ 0.05 (compared with respectively treated group) using ANOVA followed by Dunnet 
test. 
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Hot Plate Assay 
 
 
 
 
-30 0 30 60 90 120 150 180
0
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P-31 3 mg/kg
P-31 10 mg/kg
*
* *
*
*
*
***
**** *
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*
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* Morphine 5 mg/kg
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s
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Effect of P-31 (1, 3, 10 mg/kg, P.O.) or morphine (10 mg/kg, P.O.- positive control) on the hot 
plate test, in mice (n = 8).  The values were expressed as mean ± SEM of the latency to 
nociceptive behavior, in seconds. *P ≤ 0.05 compared to control group, according to two-way 
ANOVA followed by Bonferroni’s post-hoc test. 
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Effect of AK-1401 (1, 3, 10 mg/kg, P.O.) or morphine (10 mg/kg, P.O., positive control) on the 
hot plate test, in mice (n = 8).  The values were expressed as mean ± SEM of the latency to 
nociceptive behavior, in seconds. *P ≤ 0.05 compared to control group, according to two-way 
ANOVA followed by Bonferroni’s post-hoc test. 
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Effect of AK-1402 (1, 3, 10 mg/kg P.O.) or morphine (10 mg/kg, P.O., positive control) on the 
hot plate test, in mice (n = 8).  The values were expressed as mean ± SEM of the latency to 
nociceptive behavior, in seconds. *P ≤ 0.05 compared to control group, according to two-way 
ANOVA followed by Bonferroni’s post-hoc test. 
 
 
 
 
 
 
 180 
 
 
II. Antidepressant related assays 
Forced swimming test 
 
The effect of oral administration of vehicle, AK-1401 at 1, 3, 10 mg/kg, positive control 
imipramine (IMI) at 15 mg/kg, and vehicle on the swimming time (B) and immobility time (C) 
in the forced swimming test. Each column represents the mean ± S.E.M. of 10 animals. *P < 
0.05, *P < 0.01 or *P < 0.001 vs vehicle treated group (one way ANOVA followed by Dunnett´s 
test). 
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Tail suspension test  
 
The effect of oral administration of AK-1401 at the doses of 1, 3, 10 mg/kg and positive control 
imipramine (IMI) 15 mg/kg or vehicle on immobility time in the tail suspension test (one-way 
ANOVA followed by Dunnett’s test). 
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Open Field Test 
 
 
 
 
 
Open field test results, Freezing time and Total crossing:  AK-1401. 
The effect of acute oral administration of AK-1401 at 1, 3, 10 mg/kg, 
positive control diazepam (DZP) 5 mg/kg, or vehicle in the open field 
exploratory assay on freezing time (A), the total crossing (B), number of 
rearing events. Each column represents the mean ± S.E.M. of 10 animals. 
*P < 0.05 and ***P<0.001 versus vehicle treated group (one way ANOVA 
followed by Dunnett´s test). 
 
 183 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Open field test results, Number of rearing and crossing at the center:  AK-1401. 
 
The effect of acute oral administration of AK-1401 at 1, 3, 10 mg/kg, positive 
control diazepam (DZP) 5 mg/kg, or vehicle in the open field exploratory assay 
on freezing time (C) and crossing at the center of the open-field (D). Each 
column represents the mean ± S.E.M. of 10 animals. *P < 0.05 and ***P<0.001 
versus vehicle treated group (one way ANOVA followed by Dunnett´s test). 
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APPENDIX F:   
Copyright Permissions 
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Figure 4.  “Salvia_divinorum_-_Herba_de_Maria”   
Used under terms of Creative Commons 2017. 
o CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=157218 
 
Figure 8.   Reprinted by permission from Macmillan Publishers Ltd:  Copyright 2002.     
Roth, B.L.; Baner, K.; Westkaemper, R.; Siebert, D.; Rice, K.C.; Steinberg, S.; Ernsberger, P.; 
Rothman, R.B.  2002.  Salvinorin A:  A potent naturally occurring nonnitrogenous κ opioid 
selective agonist.  Proceedings of the National Academy of Sciences of the United States of 
America.  99(18):11934-11939.   
o License Number:  4053681203902. 
 
Figure 13.   Reprinted by permission from Springer:  Copyright 2003.     
Merlin, M.D.  2003.  Archaeological Evidence for the Tradition of Psychoactive Plant Use in the 
Old World.  Economic Botany.  57(3):295-323. 
o License Number:  4062980354466. 
 
 
Figure 14.  Public Domain image provided by TeunSpaans.  2017. Opium pod cut to demonstrate 
fluid extraction. 
o https://upload.wikimedia.org/wikipedia/commons/3/3b/Opium_pod_cut_to_demo
nstrate_fluid_extraction1.jpg 
 
 
Figure 15.  Public Domain image obtained from Drug Enforcement Agency.  2017.  Image of 
dried opium.   
o https://www.dea.gov/pr/multimedia-library/image-gallery/opium/opium3.jpg 
 
Figure 17.  Public Domain image provided by Mpv_51.  2017. Bayer Heroin bottle. 
o https://upload.wikimedia.org/wikipedia/commons/f/ff/Bayer_Heroin_bottle.jpg 
Figure 23.  Reprinted by permission from ASPET:  Copright 2007. 
Groer, C.E.; Tidgewell, K.; Moyer, R.A.; Harding, W.W.; Rothman, R.B.; Prisinzano, T.E.; 
Bohn, L.M.  2007.  An Opioid Agonist that Does Not Induce μ-Opioid Receptor — Arrestin 
Interactions or Receptor Internalization.  Molecular Pharmacology.  71(2):549-557. 
 
Figure 24.  Reprinted by permission from ASPET:  Copright 2007. 
Groer, C.E.; Tidgewell, K.; Moyer, R.A.; Harding, W.W.; Rothman, R.B.; Prisinzano, T.E.; 
Bohn, L.M.  2007.  An Opioid Agonist that Does Not Induce μ-Opioid Receptor — Arrestin 
Interactions or Receptor Internalization.  Molecular Pharmacology.  71(2):549-557. 
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